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Abstract
This scholarly project determined the relationship of atrial fibrillation (AF) occurrences
in COVID-19, as it is the most frequent arrhythmia in the U.S. and is driven by inflammatory
pathology. In COVID-19 positive patients with AF occurrences understanding the relationship
between these conditions could help identify patients with poor prognosis, higher morality, and
other factors earlier in the hospital course.
This single-center scholarly project was a retrospective descriptive chart review to
determine the relationship between AF and COVID-19 over a 6-month timeline in Chattanooga,
TN. Of the 565 hospitalized COVID-19 positive patients included, 82 (14.5%) had AF
occurrences. A higher proportion of patients had AF occurrences in the non- ICU setting (87.5%)
versus the ICU setting (12.5%). Of those in the ICU, 7 (100%) expired versus those in the nonICU setting (22.4%). Of those with AF, 61% survived the hospitalization compared to 39% that
expired, p < 0.001. Those with AF occurrences (median 6 days) had longer length of stay (LOS)
than those without (median 4 days). Those of male gender, older age, history of arrhythmias
(other than AF), history of AF, acute kidney injury, low eosinophil levels, and received
antibiotics during hospitalization had higher odds of having AF occurrences while hospitalized
for COVID-19. These results add to the limited research on AF occurrences in hospitalized
COVID-19 positive patients in the U.S.
Keywords: atrial fibrillation, af, afib, covid-19, coronavirus, incidence, mortality

4
Dedication
I dedicate this scholarly project to both of my grandmothers who were registered nurses;
Esther Elizabeth Harder Caine Balchunus
&
Mary LaVerne Akers Walters, for who I am named.

5
Acknowledgments
I would like to thank God for His presence in my life in the last four years and for His
many blessings. I am grateful for His leading and hope to honor Him in this new career as an
advanced practice nurse. I would like to acknowledge and thank my husband, Derek Taylor, for
all he has gone through with me going back to graduate school. He is for sure my better half. I
would like to thank and acknowledge my children, Jake & Kaia, for being patient with me as I
dedicated many years to pursue an advanced nursing degree during their childhood years.
I want to acknowledge and thank my parents, Dale & Lezlee Walters, for their
encouragement and support in going back to graduate school. They have always encouraged me
to do my best and to work hard in everything I do. I would like to thank my in-laws, Gaylene &
Daniel Taylor, for their encouragement and support. I especially want to thank my mother-in-law,
Gaylene, for her tireless effort in caring for the children in the last year of graduate school.
I would like to acknowledge and thank my project advisor Dr. Holly Gadd and her efforts
and encouragement along the way. She has gone above and beyond in helping me with late-night
edits, encouraging words, and in prayer. I would also like to acknowledge and thank my advisor,
Dr. Frances Johnson, for her guidance and encouragement throughout the process. I want to
thank and acknowledge Nancy Shiles for being my project advisor and liaison at CHI Memorial.
Nancy’s involvement was paramount to my success, and I am grateful for her involvement,
interest, and encouragement along the way.

6
Table of Contents
Acknowledgments..………………………………………………………………………..5
List of Tables………….…………………………………………………………………..9
List of Figures……………………………………………………………………………10
Chapter 1: Introduction…………………………………………………………………………..11
Background and Significance……………………………………………………………11
Problem Statement and Purpose…………………………………………………………13
PIO Question……………………………………………………………………………..14
Theoretical Framework…………………………………………………………………..14
Chapter 2: Literature Review…………………………………………………………………….19
Presentation of Literature………………………………………………………………..19
Atrial Fibrillation…..….…………………………………………………………………19
Atrial Fibrillation Pathology……………………………………………………..20
Atrial Fibrillation Risk Factors…………………………………………………..21
Atrial Fibrillation in ICU Setting………………………………………………..21
Atrial Fibrillation in Sepsis………………………………………………………22
COVID-19……………………………………………………………….……………….23
COVID-19 Pathology……………………………………………………………23
COVID-19 Risk Factors…………………………………………………………24
COVID-19 Complications……………………………………………………….24
COVID-19 and the Cardiovascular System……………………………………..25
COVID-19 and Atrial Fibrillation.………..……………………………………………..26
Mortality in AF Occurrences in COVID-19……………………………………..27

7
Summary of Literature……………………………………………………………….…..28
Chapter 3: Methodology…………………………………………………………………………29
Design ……………………………………………………………………………………29
Sample Size, Population, and Timeline...………………………………………………..29
Recruitment………………………………………………………………………………30
Protection of Human Subjects…………………………………………………………...30
Data Handling……………………………………………………………………30
Data Collection……………………………………………………….………….31
Methods of Statistical Analysis for Objectives..…………………………………………33
Chapter 4: Results………………………………………………………………………………..37
Description of the Sample……………………………………………………………….37
Demographics……………………………………………………………………………37
Descriptive Statistics……………………………………………………………………..39
Analysis of Project Research Questions…………………………………………………43
Additional Statistical Analysis…………………………………………………………..53
All Predictive Variables in AF Occurrences…..…………………………………53
All Predictive Variables in Those that Expired.………………………………….53
Ethnicity Versus Expired…………………………………………………………54
Chapter 5: Discussion……………………………………………………………………………55
Discussion of the Research Question……………………………………………………55
Observations……………………………………………………………………………..68
Limitations………………………………………………………………………………68
Implications of Future Research…………………………………………………………69

8
Application to Practice..………………………………………………………………….70
Conclusion……………………………………………………………………………….70
References………………………………………………………………………………………..72
Appendix A: SAU Institutional Review Board Approval…….………………………………….78
Appendix B: CHI Memorial Institutional Review Board Approval……………………………..79
Appendix C: Data Collection Variables………………………………………………………….81
Appendix D: EOS SLO Synthesis……………………………………………………………….82

9
List of Tables
Table 1. Comorbid Condition of COVID-19 Positive Patients…………………………………..40
Table 2. Admission Laboratory Values in COVID-19 Positive Patients…………………………41
Table 3. Onset of AF Occurrences in Relation to Hospitalization Day………………………….49
Table 4. Onset of COVID-19 Symptoms in Days………………………………………………..49

10
List of Figures
Figure 1. The Betty Neuman’s System Model & CREATION Life……………………..15
Figure 2. Ethnicity……………………………………………………………………….38
Figure 3. The Onset of COVID-19 Symptoms in Number of Days Before Admission…39
Figure 4. AF Occurrences During Admission……………………………………………41
Figure 5. Discharge Disposition……..…………………………………………………..42
Figure 6. Length of Stay by AF Initiation………………………………………………..50

11
Chapter 1: Introduction
The severe acute respiratory syndrome, coronavirus-2 (SARS-CoV2 or COVID-19)
originated in Wuhan China in the latter part of 2019. The first U.S. case of COVID-19 was
reported to the Centers for Disease Control and Prevention (CDC) on January 22, 2020, in
Washington State and has since spread to all states and U.S. territories. On March 11, 2020, the
World Health Organization declared that COVID-19 had officially reached pandemic status as it
had spread all across the world. As of December 6, 2020, more than 14.4 million cases of
COVID-19 have been detected and 280,135 people have died from the virus in the U.S. (CDC,
2020).
Background and Significance
Patients with COVID-19 are at risk for various complications including respiratory
failure, shock, acute respiratory distress syndrome (ARDS), arrhythmias, acute myocardial
injury, acute liver injury, and sepsis (Du et al., 2020). Du et al. (2020) conducted a retrospective
study of 85 COVID-19 positive patients and discovered that 50 (58.8%) developed an arrhythmia
during hospitalization. Atrial fibrillation (AF) is one of the most common arrhythmias
experienced in the U.S. according to the 50-year Framingham Study that finished in 2015
(Schnabel et al., 2015). More than 467,000 patients diagnosed with AF are hospitalized annually
in the U.S. and more than 99,000 deaths from AF occur each year (January et al., 2014).
In recent years, AF has been linked to a pro-inflammatory substrate and, patients with
certain chronic conditions have underlying low levels of inflammation that promote the
development of AF (Korantzopoulos et al., 2018). COVID-19 also has been associated with
systematic inflammatory marker surges called cytokine storms. These cytokine storms are
believed to be the basis of COVID-19 pathology and play a part in the endothelial dysfunction
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that drives its complications. COVID-19 was initially thought to only affect the lungs with
severe pneumonia; however, as research on the novel coronavirus emerged earlier this year, it
was discovered that the infection can spread across the body and create various complications in
many organ systems ranging from shock, acute kidney injury, acute liver injury, stroke,
arrhythmia, ARDS and acute cardiac injury (Wang et al., 2020). Those in the ICU were found to
have more of the above-mentioned complications versus those who were not admitted to the ICU
according to the research from China and Italy.
This novel beta coronavirus (COVID-19) is a large RNA virus that enters the body
through the oral pharynx, passes through the air passages and, down into the lungs, attaching to
the angiotensin-converting enzyme (ACE2) receptors effectively entering the body (Liu et al.,
2020). ACE2 is a component of the renin-angiotensin system (RAS) that plays a role in the
regulation of blood pressure and the immune system. ACE2 activation can lead to unchecked
inflammatory cytokines releases (i.e. IL-6, TNF-α) into the body, prothrombotic and pro-oxidant
risks that could be driving the many complications seen in COVID-19 (Liu et al., 2020). It is not
known whether viral replication can directly occur in the myocardium or related structures (i.e.
conduction system) or if the damage incurred by the cardiovascular system is by direct viral
injury or indirectly, through the host’s immune responses (Liu et al., 2020).
Research thus far has mostly come from China and Italy and has not been conducted in
ethnically diverse populations, which does not give a complete picture of COVID-19 in the U.S.
Furthermore, little is known about the patterns and problems related to arrhythmias in COVID19 patients. There is mixed information about what kind of arrhythmias, prevalence, and
incidence is seen currently in patients with COVID-19. Most of the research does not include
data about arrhythmias or does not mention AF at all. While some research does mention
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arrhythmias as a complication of COVID-19, there is no differentiation, no correlation to
mortality, and no casual relationships. With the vast numbers of patients being admitted to
hospitals daily, more research is needed to investigate the relationship of each complication
identified in patients with COVID-19 and determine its role in the course of patients’ illness.
Determining the relationship of AF, as it is the most frequent arrhythmia and is driven by
inflammatory pathology, in COVID-19 positive patients, will help treat and could identify
patients with poor prognosis earlier in the hospital course, allowing providers to intervene sooner
and prevent systemic sequelae of COVID-19. This DNP project will also add to the limited
research regarding comorbid relationships with COVID-19 and how COVID-19 interacts and
influences other disease processes.
Problem Statement with Purpose
I hypothesize that hospitalized COVID-19 patients with atrial fibrillation occurrences
have higher mortality rate and poorer outcomes than those without atrial fibrillation. Secondary
research questions are as follows:
•

What is the overall incidence of AF in COVID-19 positive patients admitted to the
hospital?

•

Is there a difference in the incidence of AF in COVID-19 positive patients admitted to the
ICU versus those in non-ICU settings?

•

Are there differences in LOS and mortality for COVID-19. positive patients who have AF
occurrences versus those who do not?

•

Are there differences in LOS and mortality for COVID-19 patients who have AF
Occurrences in ICU versus non-ICU settings?

•

What demographic factors and comorbid conditions are associated with AF occurrences?
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•

How are typical COVID-19 treatments related to AF occurrences?

•

Are admission laboratory tests predictive or associated with AF occurrences in COVID19 positive patients?

•

Is there a pattern in the course of COVID-19 illness for AF onset?

•

Are AF occurrences associated with an increased incidence of COVID-19 complications?

•

Are high levels of supplemental oxygen and invasive mechanical ventilation associated
with AF occurrences in COVID-19 positive patients?

Research Question
The population investigated is hospitalized COVID-19 positive patients with atrial
fibrillation (AF) occurrences.
P: Hospitalized COVID-19 patients/ Atrial fibrillation occurrences
I: No intervention
O: Incidence, Mortality, and related factors
Theoretical Framework
Betty Neuman’s systems model (Figure 1) is a cyclical model of energy exchange
centering around the patient (Skyward, 2010). The system tends toward balance and stability;
however, diseases can disrupt the dynamic energy exchange and can move the body’s system
away from stability. Diseases disrupt normal physiologic functions and reroute energy to
maintaining the patient’s vital functions and basic structure. Stressors interrupt balance and
create an unsteady state with the patient.
COVID-19 is a virus that disrupts various body systems creating instability in the
patient’s vital and most basic functions. Patients who have comorbid conditions seem to have
fewer ‘lines of resistance’ that protect the inner circle and can have an altered state of wellness.
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Those of older age are also at higher risk, as their ‘lines of resistance’ are not as efficient as they
once were, making them increasingly vulnerable to illness and infections. The COVID-19
pandemic has brought about unique challenges for healthcare professionals and patients.
Figure 1
The Betty Neuman’s System Model and CREATION Life

For healthcare professionals, managing patient care in a pandemic environment has made
enormous changes by initiating social distancing and mask-wearing in the hospital for
employees, visitors, and patients. These measures were unfamiliar to most and had not been
utilized on a global scale since the 1918 influenza over 100 years ago. There have been
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subsequent outbreaks and epidemics (i.e. MERS, SARS, H1N1), however, they never reached
pandemic status.
Approaches to patient visitation guidelines changed early in the pandemic and then
restrictions later loosened as events unfolded. Patients did not have access to their family
members, spiritual support, or support systems in hospitals, due to visitation restrictions during
the early part of the pandemic. At one time, no visitors were allowed to enter the hospital with
patients. Although those restrictions have been lightened, patients who are COVID-19 positive
are still not allowed any visitors to halt transmission and spread of the disease. Health care
providers, nurses, and patient care staff rely on families, spiritual support, caregivers, and other
support systems to provide support to patients, provide information when patients cannot
advocate, and increase patient safety. The mental and physical stress of being admitted to the
hospital without having their support system could have negative effects on patient health
outcomes. Early intervention can mitigate stressor effects on the body and can help support those
‘normal lines of defense’.
CREATION health, now transitioning to the name CREATION life in 2021, is a set of 8
essential principles for a healthy and long life, that can help individuals strengthen their ‘normal
lines of resistance’ to prevent disease. The 8 essentials are choice, rest, environment, activity,
trust, interpersonal, outlook, and nutrition (Cummings, Reed, & Chobotar, 2014). Betty
Neuman’s model encourages early intervention to mitigate the effects of stressors on health to
support the ‘normal lines of defense’. The power to change health lies in the hands of each
person. Choosing to participate in their healing process is by conscious choice.
Choice is the essential first step in claiming health ownership and participating daily in
making good choices for future health (Cummings, Reed, & Chobotar, 2014). While patients
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admitted to the hospital for COVID-19 have very few choices at this stage of illness, patients can
choose to have a positive outlook on their situation. Patients must choose not to worry about
what is out of their control and do everything they can do to recover. Rest is the second essential,
however restful and adequate sleep may be difficult to achieve in a healthcare setting. Caregivers
can promote healing by bundling care and providing adequate rest periods. A clean patient
environment is the third essential that promotes healing. Touching or holding a patient's hand
provides therapeutic healing, especially while families cannot be there to hold their own loved
one's hands. Not only does physical touch encourage a healing environment but a gentle word
can promote healing as well. It is prudent that healthcare professionals be aware of and be
educated on cultural practices or preferences, as touch may not always be therapeutic in every
culture. Encouraging physical activity when patients are stable enough to participate prevents
physical deconditioning and promotes recovery.
Creating trusting interpersonal relationships with patients and families is the essence of
nursing and is essential in the caregiver role. Interpersonal relationships are difficult to maintain
during hospitalization, especially when patients are unable to communicate with family
members. Healthcare providers and nurses can help offset the lack of face-to-face contact by
giving frequent phone updates, discussing their loved one's care over the phone, with permission
of the patient, and utilizing technology to connect the patient with their family members (i.e.
FaceTime, Zoom). Choosing a positive outlook is like good medicine. Anger and negativity are
like poison to the body (Cummings, Reed, & Chobotar, 2014).
Nutrition is key for healing and while patients cannot choose what kind of food, they are
served in the hospital it is essential for healthcare providers to know how poor nutrition can
affect illness. Early feeding protocols should be utilized to prevent malnourishment in patients
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who cannot eat and to treat electrolyte and fluid balance disturbances. While not all of these
essentials can be utilized in a hospital setting, many can be implemented by patients and staff
with little or no modification. Early intervention is the key to success and discovering the
relationship between AF and COVID-19 will help providers intervene earlier in those patients
who are at higher risk for poor outcomes.

19
Chapter 2: Literature Review
CINAHL Complete, Google Scholar, and MEDLINE Complete databases and search
engines were used to find prior literature on the subject of AF in hospitalized COVID-19
patients. The goal was to find and include published original research from 2016 to 2020 in
English. Terms used were AF, atrial fibrillation, A fib, COVID-19, SARS-CoV2, and
coronavirus. As there were few studies within these timeframes and on COVID-19 specifically,
search parameters were broadened to include AF in critical illness, the ICU, and in sepsis.
Presentation of Literature
Prior literature highlighted the ongoing need for study and replication in the topic of AF
in COVID-19. There were four studies found that specially addressed AF occurrences in
COVID-19 positive patients. First, exploring AF, its pathology, risk factors, and its interaction in
sepsis and in the ICU setting. Secondly, literature on COVID-19 pathology, risk factors,
complications, and cardiovascular disease and COVID-19. Third, exploring COVID-19 and AF
and how their pathology intermingles, and what the mortality shows within these populations.
Atrial Fibrillation
Atrial fibrillation is a supraventricular tachycardia that causes stagnation of blood inside
the chambers of the heart due to inadequate pumping action of the atria (January et al., 2014).
The quivering of the atria is paired with an irregularly irregular response from the ventricles,
often inducing tachycardia. The American College of Cardiology categorizes AF into three basic
types; paroxysmal AF, persistent AF, and permanent AF, which are based on timing and cessation
of the AF episodes (Ferri, 2020). Paroxysmal AF is classified as more than one episode and
terminated with or without intervention within 7 days. Persistent AF is classified as episodes that

20
last longer than 7 days and permanent AF is when clinicians stop pursuing rhythm restoration
and focus on rate control.
The pooling of blood associated with AF occurs most often in the left atrium extending
into the left atrial appendage. The left atrial appendage is a normal physiological out-pouching
just adjacent to the left atrium. There clots can form and move to the brain, causing a stroke.
According to the American Heart Association (2020), stroke continues to be the leading cause of
morbidity in the U.S. AF is associated with certain comorbid conditions that increase the
likelihood of developing AF; increasing age, hypertension, diabetes mellitus, myocardial
infarction, valvular heart failure, obesity, obstructive sleep apnea, cardiothoracic surgery and
hyperthyroidism (January et al., 2014). Atrial fibrillation has other complications that include;
heart failure, cognitive impair and dementia, myocardial infarction, progressive chronic kidney
disease, lower quality of life, sudden cardiac death, and increased risk of all-cause mortality
(Chen et al., 2018).
Atrial Fibrillation Pathology
Atrial fibrillation is linked to ACE2 up-regulation and has been associated with low-grade
inflammation and increased levels of pro-inflammatory cytokines, particularly in obesity,
hypertension, coronary artery disease, cardiac surgery, and cardiac ablation (Hu et al., 2015).
Pathogenesis is complex and not completely understood even today. Radiofrequency ablation is a
procedure that is intended to help eliminate AF. Ablation induces an inflammatory response in
reaction to a thermal injury (Hu et al., 2020). Several novel mechanisms that are attributed to AF
pathogenesis have been proposed such as atrial fibrosis, adipose tissue, atrial remodeling, and
hyper-coagulability (Lau et al., 2016). However, atrial fibrosis is not developed in just days,
making this an unlikely pathology in COVID-19. Excess adipose tissue in obese patients,
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remodeling of the atria, and hyper-coagulability could be involved in the pathology that drives
COVID-19. Patients that present with AF may have a pre-existing substrate that is triggered by
COVID-19 infection (Gwalko et al., 2020). These pre-existing substrates are risk factors for AF
that increase the likelihood of having AF occurrences.
Atrial Fibrillation Risk Factors
Older age is a common risk factor for the development of AF. The 50-year Framingham
study showed that those over the age of 60 are at increased risk for AF, along with those who
have comorbid conditions such as high BMI, diabetes, heart failure, valvular disease, and
obstructive sleep apnea (Schnabel et al., 2015).
AF, in the acute care setting, is common and often associated with poorer outcomes.
More than 467,000 patients diagnosed with AF are hospitalized annually in the U.S. and more
than 99,000 deaths from AF occur each year (January et al., 2014). The most acute complication
of AF is stroke, causing about 7% of deaths. Sudden cardiac death (22.25%), heart failure
(15.1%), and non-cardiac deaths (35.8%) are much more abundant complications of AF death
that were identified in the The Randomized Evaluation of Long-Term Anticoagulant Therapy
(RE-LY) randomized prospective study (Marijon et al., 2013). Interventions are needed to
prevent these other more abundant causes of death, which modern medicine has inadequate
answers for at this time. The lower stroke rate could be attributed to early anticoagulant
protocols. There is a need for further research to determine what interventions or therapies could
halt these pathological mechanisms that drive deaths in the AF population.
Atrial Fibrillation in the ICU Setting
There has been disagreement on whether AF is associated with the illness severity or AF
itself. During a 4-day prospective observational study, 236 of 1,770 patients (13%) in the ICU
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developed any form of AF (Shaver et al., 2015). Of the patients who developed any form of AF,
30% died during hospitalization compared with 17% with no AF (p<0.001) (Shaver et al., 2015).
After controlling for potential confounding factors, both types of AF remained significantly
associated with increased risk of mortality (OR 1.62, 95% CI 1.14-2.29, p=0.007) (Shaver et al.,
2020). Types of complications are different for recurrent AF versus new-onset AF. Patients with
new-onset AF were more likely to have organ failure and shock while those with recurrent AF
were older and had more comorbid conditions. Shaver et al. (2015) found that the development
of AF was associated with a 62% increased risk of mortality in ICU patients. A meta-analysis
found a statistically higher mortality rate in patients with AF versus those without AF in the ICU
(OR 2.70; 95% Cl 2.43-3.00; p<0.001) (Kanjanahattakij et al., 2018). The increased mortality in
the ICU associated with AF development is a significant finding and one that deserves great
attention when developing treatment protocols.
Atrial Fibrillation in Sepsis
In a multi-center retrospective cohort study, new onset AF was studied to determine
mortality among the critically ill. Researchers determined the prevalence to be 10.3% which is in
keeping with historical studies. They did not find that AF was an independent risk factor
associated with mortality in the general critically ill population. However, Fernando et al. (2020)
determined that new-onset AF was associated with higher hospital mortality among ICU patients
in certain subgroups that include; suspected infection (OR 1.21 [95% CI 1.08-1.37]), sepsis (OR
1.24 [95% CI 1.10-1.39]), and septic shock (OR 1.28 [95% CI 1.14-1.44]). It was determined
that those with sepsis have a 6-fold increased risk of developing AF. A subgroup analysis of
sepsis found a higher mortality rate among those with AF (OR 2.32, 95% Cl 1.88-2.87, p <
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0.001) (Kanjanahattakij et al., 2018). This raises questions about the relationship between AF
and infection, infection acting as a substrate for the AF development, and poor prognosis.
COVID-19
COVID-19 or SARS-CoV2 is not the first coronavirus outbreak to occur in recent history.
In late 2002, severe acute respiratory distress syndrome coronavirus (SARS-CoV) broke out
causing 8,098 reported cases globally, killing 774 people with a case fatality rate of 9.7%
(Petersen et al., 2020). In 2012, the Middle Eastern respiratory distress syndrome (MERS-CoV),
another deadly coronavirus, killed 858 people in 27 countries with a case fatality rate of 34%
(Petersen et al., 2020). Unfortunately, COVID-19 has killed more people than both SARS and
MERS outbreaks combined and reaching pandemic status. A higher transmissible rate (R score),
a longer incubation period of 4-12 days, a higher portion of mild illness, and higher viral peak at
5 days making COVID-19 particularly difficult to contain and presents separate challenges than
prior coronavirus epidemics in controlling and eradicating the virus (Petersen et al., 2020).
COVID-19 also has a unique pathology that was not seen in prior coronaviruses.
COVID-19 Pathology
COVID-19 is a large RNA virus that enters the body through the oral pharynx and lungs,
attaching to the ACE2 receptors effectively entering the body (Liu et al., 2020). ACE2 is a
component of the renin-angiotensin system (RAS) that plays an important role in regulating the
blood pressure and immune systems’ stress response. ACE2 can be found in the lungs as well as
the gut, kidneys, liver, neurons, and vasculature (Liu et al., 2020). ACE2 receptors have recently
been associated as the mode of entry for the COVID-19 virus. COVID-19 has a broad range of
complications ranging from coagulopathy, acute kidney injury, thromboembolism, stroke, and
cardiovascular complications because the receptors are in many places throughout the body.
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Early in the pandemic, early research pointed to effects of COVID-19 on the
cardiovascular system. Shi et al. (2020) and Lala et al. (2020) were able to look at the
prevalence and impact of patients with myocardial injury who were hospitalized for COVID-19
infection. They reported association with higher mortality among those with cardiac injury
versus in those without injury (42 of 82 [51.2%] vs 15 of 334 [4.5%]; p < 0.001). Cardiovascular
pathology, incidence, and complications were not well understood early on in the pandemic,
leaving clinicians without guidelines and tools to treat patients.
COVID-19 Risk Factors
Risk factor stratification for COVID-19 has been seen in the earliest research studies
conducted in China. Almost a quarter, 23.7% of those diagnosed with COVID-19 had at least one
comorbid condition (Guan et al., 2020). Those that were determined to be more severe were
older age and had comorbid conditions, even though their exposure history was similar to those
that were not in serious condition. Guan et al. (2020) identified that patients with comorbid
conditions and of older age were more likely to have severe disease than those who had nonsevere disease (38.7% vs. 21.0%). Of 1099 hospitalized COVID-19 patients, 173 were identified
with severe COVID-19 and 926 were non-severe (Guan et al., 2020).
COVID-19 Complications
Patients with COVID-19 are at risk for various complications including respiratory
failure, shock, acute respiratory distress syndrome (ARDS), arrhythmias, acute myocardial
injury, acute liver injury, and sepsis (Du et al., 2020). Endothelial disruption and ACE2 receptors
throughout the body is thought to contribute to the increased rates of systemic complications
(Froldi & Dorigo, 2020).
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Overall, research points to comorbid conditions as major risk factors for contracting COVID19. Early on, there were no specifics addressed, however, progressive research indicated that
cardiovascular disease was at the top of the list for contracting COVID-19. Inciardi, et al., (2020)
conducted a study in Italy comparing COVID-19 patients with and without a cardiac history.
Mortality was significantly higher in the cardiac group vs. the non-cardiac group (35.8% vs.
15.2%, p<0.001).
COVID-19 and the Cardiovascular System
Myocarditis is seen in COVID-19 patients as the virus can settle in the myocardium and
vascular endothelium. A single-center retrospective observational study in Wuhan China
included 52 critically ill patients that showed 12 (23%) of those patients experienced cardiac
injury evidenced by elevation of cardiac markers. Of those who had a cardiac injury, only 3
(15%) survived; 9 (28%) were non-survivors (Yang et al., 2020). Statistical calculations were not
done to determine if these numbers were statistically significant, likely due to the small sample
size. Cardiac injury was tracked by high-sensitivity troponin I (hsTNI) and the mean was 161.0
(IQR 41.8-766.1 pg/ml) (Yang et al., 2020). Non-survivors were more likely to be men (67%),
older age (mean=59.7), comorbid conditions (40%), and experience fever (98%) as a symptom of
COVID-19 (Yang et al., 2020).
Another study that was conducted in Seattle Washington in February 2020, showed that 2
out of 24 patients had elevations in their troponin early on in their hospital course (maximum
value, 0.80mg/dl). No conclusions were drawn and there were limitations of the data due to
sample size (Bhatraju et al., 2020). Du et al. (2020) found that 38 (44.7%) of the 85 patients have
an acute myocardial injury, however, there was no tracking of troponin levels. In studies by Long
et al. (2020), Lala et al. (2020), and Shi et al. (2020) researchers discussed how an acute
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myocardial injury impacted patients who were hospitalized with COVID-19. Possible
mechanisms by which COVID-19 induced AF might come about are the reduction in ACE2
receptor reduction, which can increase inflammatory cytokine storms, direct endothelial damage,
electrolyte and fluid disturbances in the acute phase of illness with up-regulation of adrenergic
drive (Gwalko et al., 2020).
COVID-19 and Atrial Fibrillation
Much of the research about COVID-19 and AF is limited and brief. There is little
delineation in type of AF and relationship with COVID-19. Du et al. (2020) discovered that 50
out of 85 COVID-19 positive patients or 58.8% developed an arrhythmia during the
hospitalization. A retrospective study in Wuhan China reported 23 of 138 (16.7%) COVID-19
positive patients had AF occurrences during their hospitalization and further delineated the
differences in AF incidence between the ICU (44.4%) versus the non-ICU (6.9%) setting, p <
0.001 (Wang et al., 2020). This could further alert clinicians to a link between AF and severity of
disease.
In a retrospective descriptive study in Pennsylvania, Bhatla et al. (2020) showed 39 (6%)
of patients had a history of AF and of those 23% were ICU patients that died. In contrast, of the
non-ICU patients with a history of AF there were only 2% that died. This creates a 10-fold odds
of death when having a history of AF and contracting COVID-19 even when adjusting for other
variables. This suggests that a history of AF might be an indicator for higher mortality. Bhatla et
al. (2020) concluded that COVID-19 is not the direct cause of AF but the severity and systemic
illness was causing dysrhythmias.
The single-day snapshot survey investigated the prevalence of arrhythmias among 132
patients who were clinically stable in seven COVID-19 units at a hospital in Milan, Italy.
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Patients who received ICU care or who were clinically unstable were excluded from the study.
The single-day snapshot study reported that 16 (12%) patients had a history of AF (paroxysmal,
n=12; permanent, n=4) (Sala et al, 2020). On the study day, only 4 patients experienced new AF
episodes and 4 were in chronic AF (Sala et al., 2020). Limitations of this study would include the
paroxysmal nature of AF and limited detection of AF on a single day snapshot, however, no
limitations were discussed in the study.
Among the 138 participants who were included in a retrospective study at the Zhongnan
Hospital of Wuhan between January 1, 2020, and January 28, 2020, 23 patients in the cohort
(16.7%, p=<0.001) experienced complications of arrhythmias, 16 of which were in the ICU
(Wang et al., 2020). Arrhythmia was among the top three complications in the cohort, others
included acute respiratory distress syndrome (ARDS) and shock. By February 3, 2020, on the
last day of data collection, 26% required ICU care, 34.1% were discharged and 6 died (4.3%),
and 61.6% remained hospitalized (Wang et al., 2020). There was no further categorization or
delineation of arrhythmias among the 138 participants. Other studies provided even less
information about arrhythmia involvement.
Of 99 patients included in a retrospective study at the Jinyintan Hospital in Wuhan China
between January 1, 2020, to January 20, 2020, 40 (40%) of the patients had a history of
cardiovascular or cerebrovascular diseases (Chen et al., 2020a). However, there was no mention
of arrhythmias as a complication within this cohort or further definition of what was included in
a history of cardiovascular or cerebrovascular disease.
Mortality in AF Occurrences in COVID-19
There is higher mortality associated with illness (i.e. sepsis) and atrial fibrillation, however,
research thus far has not been able to provide mortality data on the relationship between AF and
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hospitalized COVID-19 patients. There have been some loose associations and mortality rates
ranging from 1.4% - 4.3% (Guan et al., 2020; Wang et al., 2020; Bhatla et al., 2020), but these
are often associated with general COVID-19 mortality. Bhatla et al. (2020) associated AF with
in-hospital mortality (OR 6.73; 95% CI 2.52-17.98) but that was found to be not statistically
significant after multivariate analysis. Sudden cardiac arrest was the only arrhythmia type to be
independently associated with acute hospital mortality (Bhatla et al., 2020). Bhatla et al. (2020)
identified several limitations, unmeasured factors that apply to the severity of illness could
explain why there is a significant incidence of AF and NSVT occurring in patients with COVID19.
Summary of Literature Review
Literature shows that AF is a common arrhythmia around the world. The COVID-19
pandemic has showed a new perspective in how inflammatory pathology and comorbid
conditions like AF, could be linked together. Those with AF in the outpatient setting are seen to
have low mortality, but, this literature is limited and has not been replicated as of yet. Of those
in the hospital setting, the literature correlates with longer hospital stays and higher mortality,
especially in the ICU settings. Literature has, thus far, been unable to show a direct causal
relationship between AF and COVID-19. AF occurrences in COVID-19 are more in line with the
patients overall severe condition, however, AF may be a marker for severity of illness.
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Chapter 3: Methodology
The purpose of this DNP project is to discover the relationship between AF and COVID19 and to determine length of stay, mortality and other related factors among hospitalized
patients with AF occurrences.
Design
The DNP scholarly project was a retrospective descriptive quantitative chart review to
investigate the relationship between AF and COVID-19 positive patients. This scholarly project
took place at a hospital in southeastern Tennessee in the city of Chattanooga.
Sample Size, Population, and Timeline
The timing of this project is of the utmost importance to make sure there are adequate
numbers of participants and to make provisions for changing treatment protocols. The Tennessee
Department of Health reported an upswing in the southeastern region of TN of COVID-19
positive cases that occurred just before July 2020 (TN Department of Health, 2020). The primary
investigator collected data starting June 1, 2020, which occurred after the “stay at home order”
was retracted by Tennessee’s Governor, Bill Lee. During March, April, and May, case numbers
were low and treatment protocols were rapidly changing, and hospitalized COVID-19 cases at
that time would likely be insufficient to have an adequate G*power. June 1, 2020, through
November 30, 2020 timeline ensured adequate numbers of patients in the participant pool during
six months and ensured a steadier state of treatment protocols. Sampling from one facility will
limit the number of cases but will provide for treatment consistency.
A priori g*power was calculated to determine the adequate number of participants needed
to reflect strong data in the analysis. We needed a minimum of 143 participants to maintain a
g*power of 0.80 with a medium effect size and alpha of 0.05. G*power analysis using small
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effect size and higher power requires sample sizes of greater than 1000 subjects. Health
Department statistics show only 364 hospitalized cases in Hamilton County between June and
October of 2020 (TN Department of Health_2, 2020). There are 3 major hospital systems in the
Chattanooga area and the 364 hospitalized patients are divided among all three facilities. The
sample size was maximized to as many charts as available that meet DNP project criteria from
June to November of 2020, to maximize the g*power and to take into consideration of a smaller
effect size. Timing of data collection was of utmost importance to obtain an adequate sample
size. It additionally provides early information about AF that is needed for refining treatment
protocols.
Recruitment
The participants were determined by the International Classifications of Diseases 10th
revision (ICD-10) code via electronic health record (EHR). The patients’ diagnosis of COVID19, which is represented by a ICU-10 code of U07.1, was included in the scholarly project. The
participant’s records were only accessible after securing IRB board approval from both Southern
Adventist University and CHI Memorial corporate’s IRB in Englewood Colorado. Since the
scholarly project was retrospective, participant informed consent was not necessary.
Inclusion and Exclusion Criteria
This DNP project included participants who were 18-89 years old, admitted to inpatient
status, the first admission for COVID-19, and COVID-19 positive. Patients who were excluded
from the DNP project are those who had a negative COVID-19 test, were older than 89 or
younger than 18, and were not admitted for inpatient care.
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Protection of Human Subjects
Data Handling
Medical Record Numbers (MRN) were collected from each participant to link with other
de-identified data. Each participant was assigned a unique and unrelated ID number on a
password-protected and encrypted file. The primary researcher was the only one with access to
the MRN/ID electronic file and this document is stored on CHI Memorial’s server. All other
data/variables about participants were entered into de-identified HIPPA compliant data fields in a
non-cloud-based Microsoft Excel. The de-identified data was kept on Memorial’s server until all
data collection was completed and then it was transported to Southern Adventist University for
SPSS analysis. The de-identified data was only accessible to my faculty supervisor Dr. Holly
Gadd, CHI Memorial’s employees assisting in EHR access, project mentor and chairperson of
the EBP committee at CHI Memorial Nancy Shiles, and a statistician if used. The primary
researcher has completed the required Citi-Training modules required by Southern Adventist
University and additional training required by CHI Memorial.
Data Collection
Data collection started after IRB approval was received. The researcher received access
to the electronic health record (EHR) EPIC to obtain participants and their health data by the
Health Information Management (HIM) Department. The researcher will utilize Microsoft Excel
to store the data and SPSS version 25 for data analysis. EHR access was the only requirement for
the DNP project. No personal contact with patients took place for this scholarly project.
Descriptive data were collected including age, gender, ethnicity, weight, height, BMI,
presenting oxygen saturation, and the onset of symptoms calculated in days before admission.
Data on comorbid conditions was collected including any history of atrial fibrillation,
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arrhythmias other than AF, valvular heart disease, hypertension, hyperlipidemia, myocardial
infarction, coronary artery disease, pacemaker or defibrillator, heart failure, diabetes mellitus or
pre-DM, chronic kidney disease, stroke or TIA, cancer, obstructive sleep apnea, chronic
obstructive pulmonary disease, asthma, or history of clots (including pulmonary embolism or
deep vein thrombosis). As it was difficult to determine exactly when patients had their history of
cancer diagnosis all prior diagnosis was collected. The patient’s length of stay and whether the
patient received care in the ICU or non-ICU setting during their stay were collected.
Specific COVID-19 treatment information was collected such as steroids, antiviral drugs,
convalescent plasma, antibiotics, and pharmacological DVT prophylaxis. Inflammatory markers
and prognostic indicators for COVID-19 which are currently being used at the study location of
interest include lymphocytes, eosinophils, neutrophils, d-dimer, CRP, troponin I, and serum
creatinine. It was determined that COVID-19 patients experienced complications related to the
virus that included arterial and/or venous thromboembolism, altered mental status or
encephalopathy, shock, acute kidney injury, acute cardiac injury, other arrhythmias, acute liver
failure, respiratory failure, or bacterial co-infections. Pulmonary interventions were determined
as most patients with COVID-19 have pulmonary involvement. Two groups were made to
delineate types of invasive (i.e. intubation) versus non-invasive ventilatory (NIV) support (i.e.
nasal cannula, simple mask, oxymizer, non-rebreather, vapotherm, high-flow, and CPAP/BiPAP)
was needed. Patients that required greater than 50% FiO2 or less than 50% FiO2 were divided
into two dichotomous nominal categories. The onset of AF was calculated in the number of days
and recorded as a separate variable. LOS was calculated and measured to see if those patients
with AF had a longer LOS than those without AF.
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Since the patient’s chart review was retrospective, the primary researcher did not
anticipate any subjects being lost to follow up or hospitalized, however, there was a possibility
that those with more extended and difficult hospital stays might still be hospitalized 30 to 60
days after the end of November 30, 2020. However, in the end, there were no participants lost to
follow up. Finally, discharge status was collected (home self-care, home with home health, home
with hospice, skilled nursing facility, transfer to a psychiatric hospital, left against medical
advice, expired on inpatient hospice, expired, transferred to other acute care hospitals).
Methods of Statistical Analysis for Objectives
What is the Overall Incidence of AF in COVID-19 Patients Admitted to the Hospital?
To determine new-onset AF diagnosis during COVID-19 hospitalization, a frequency
calculation was done to determine how many had a history of AF and AF occurrences. These
two variables were subtracted from each other to determine the total number of new-onset AF
patients in the entire population and percentage calculations were also run to determine
incidence.
Is There a Difference in the Incidence of AF in COVID-19 Positive Patients Admitted to the
ICU versus the Non-ICU Settings?
A test of group differences was run on the dependent variable (DV), AF occurrences, and
the independent variables (IV) of non-ICU and ICU settings. The proposed test was the chi
square goodness-of-fit to determine the difference in the ICU and non-ICU setting.
Are there differences in LOS and mortality for COVID-19 patients admitted to the hospital
who have AF occurrences versus those who do not?
A test of group differences was run on the DV, LOS (scale), and on the independent
groups of IV, AF occurrences. The proposed test is the independent samples t-test, however
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since the LOS was not normally distributed, we used Mann-Whitney U test as a nonparametric
alternative. For testing mortality, we used a test of group differences by comparing the DV,
expired versus survived variable to the IV, AF occurrences. The proposed test used was chi
square goodness-of-fit.
Are There Differences in LOS and Mortality for COVID-19 Positive Patients Who Have AF
Occurrences in ICU Versus Non-ICU Settings?
To determine the differences in LOS and mortality (DV) in those who have AF in both
the ICU (IV) versus the non-ICU setting (IV). The proposed test for mortality is the chi square
goodness of fit for this dichotomous nominal variable. The proposed test for LOS was the MannWhitney U non-parametric alternative since the LOS sample was positively skewed and a scale
variable.
What Demographic Factors and Comorbid Conditions are Associated with AF Occurrences?
Simple correlations will be done to determine associations of significance in those that
have AF. Using the Spearman’s correlation, non parametric alternative, to determine if age, BMI,
and SaO2 (all scale variables) are significantly associated in patients with AF occurrences. Using
Pearson’s chi square to determine significance association amongst ethnicity and gender
(categorical nominal) in patients with AF occurrences. Finally to determine if comorbid
conditions are associated to AF occurrences using the Fisher’s exact test.
Following examination of basic correlations, binary logistic regression will be used with
significant variables to build a model for prediction of AF, based on demographics and
comorbidities. The dependent variable will the those with AF occurrences and the independent
variables are the variables (both scale and nominal) that are determined to be significant
variables.
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How are Typical COVID-19 Treatments Related to AF Occurrences?
Typical COVID-19 treatments (dichotomous categorical variables) and a Fisher’s exact
test will be used to determine association with patients who have AF occurrences. Following the
examination of basic relationships, binary logistic regression will be used with significant
variables to build a model for prediction of AF occurrences based on typical COVID-19
treatment. The dependent variable is those who have AF occurrences and the independent
variables are the typical COVID-19 treatment used during the specified timeframe of data
collection.
Are Admission Laboratory Tests Predictive or Associated with AF Occurrences in COVID-19
Positive Patient?
Simple correlations will be done to determine associations of significance with AF using
Spearman’s rho due to the lack of normality. Following examination of basic relationships,
binary logistic regression will be used with significant variables to build a model for prediction
of AF based on admission lab values. The dependent variable is those with AF occurrences and
the independent variables are the laboratory tests.
Finally, binary logistic regression will combine the significant demographics, comorbidities,
treatments, labs to attempt to build a model of the best prediction of AF occurrences.
Is There a Pattern in the Course of COVID-19 O Illness for AF Onset?
Variable to be examined would be the number of days to AF onset from the admission
date and symptom onset. The proposed tests needed would be descriptive statistics to calculate
the mean, standard deviation, median, mode, and range. From these calculations, it could be
determined if AF is associated with early or late-onset in hospitalized patients.
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Are AF Occurrences Associated with an Increased Incidence of COVID-19 Complications?
The complications of COVID-19, as well as AF, will be recorded as nominal dichotomous
data. Test of associations will be done with contingency table and chi-square test of significance
of the frequencies found among the complications experienced in the sample.
Are High Levels of Supplemental Oxygen and Invasive Mechanical Ventilation Associated
with AF Occurrences in COVID-19 positive patients?
Atrial Fibrillation will be a nominal variable. Pulmonary interventions (invasive
mechanical ventilation versus NIV and FIO2 > 50% versus < 50%) are dichotomous nominal
variables and the proposed test is Fisher’s exact test. Following examination of basic
relationships, a logistic regression model was used to build a model for predicting AF
occurrences based on pulmonary interventions. AF is the DV and prediction variables are the IV
in these calculations. Of those significant variables, an additional reduced logistic regression
model was performed to determine the association/relationship.
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Chapter 4: Results
This DNP scholarly project explores the relationship of AF in COVID-19 positive
patients to determine if patients who have AF occurrences have higher mortality than those that
do not. Additionally, the project describes AF characteristics, patterns, and relationships to other
variables.
Description of the Sample
At the study facility, 1,933 patients were COVID-19 positive between June 1, 2020, and
November 30, 2020. Of those, 612 patients met inclusion criteria of inpatient admission, first
time COVID-19 admission (as some patients had multiple COVID-19 admissions), COVID-19
positive, and less than 89 and older than 18. An additional 47 patients were excluded because
they were determined to be incidentally COVID-19 positive, becoming positive towards the end
of their hospitalization and/or upon screening for transfer to Skilled Nursing Facilities or due to
pre-procedure screening protocol. Originally an a priori 143 was calculated to meet a g*power of
0.80, medium effect size, and an alpha of 0.05. However, the primary investigator obtained 565
patients that met inclusion and exclusion criteria and included them in the DNP project.
Demographics
Of the sample, 311 (55%) identified as male and 254 (45%) as female. No participants
identified as genders other than male or female. The median age of participants was 69 years old,
while the minimum age was 20 and the maximum 89. Of the participants, 77% were White,
18.4% Black, 3.4% Hispanic, 0.4% American Indian, 0.4% Asian, and 0.5% of undetermined
ethnic background see (Figure 2).
Height, weight and body mass index (BMI) were obtained from all participants. The
median BMI was 30.86, while the minimum was 14.27, and the maximum was 88.50.
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Figure 2
Ethnicity

Upon presentation to the hospital or initial medical contact, such as Emergency Medical
Services (EMS), the lowest SaO2 was 29% and the highest was 100%. Median oxygen saturation
was 88%. All SaO2 levels were on room air or at their reported baseline home oxygen rate.
COVID-19 onset of symptoms was reported in the number of days before admission.
The median number of days was 7 days. The minimum was reported as 1 day and the maximum
of 50 days. Figure 3 presents a visual representation shows the range of days of the onset of
COVID-19 symptoms.
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Figure 3
The Onset of COVID-19 Symptoms in Number of Days Before Admission

Descriptive Statistics
The entire population of this study was COVID-19 positive (100%) and admitted to
inpatient status. Overall, 29 (5.1%) received ICU care, 437 (77.3%) non-ICU care. A subset of
the population received both ICU and non-ICU care 99 (17.5 %). The longest length of stay
(LOS) was 60 days and the shortest was 1 day. Median LOS was 4 days and the mean 6.9 days.
Of the 565 patients admitted, 110 patients had a prior history of AF 19.5%. Hypertension
439 (77.1%) was the most frequent comorbid condition while valvular heart disease 40 (7.1%)
was the least, comorbid condition in the sample. The frequencies of all other comorbid
conditions are displayed in Table 1.
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Table 1
Comorbid Conditions of Hospitalized COVID-19 Positive Patients
Comorbid Conditions
History of AF*
Other Arrhythmias
Valvular Heart Disease
Hypertension
Hyperlipidemia
Myocardial Infarction
CAD*
Pacemaker or AICD*
Heart Failure
DM* or Pre-diabetes
CKD*
Stroke or TIA*
Cancer
OSA*
COPD*
Asthma
History of Clots*

Percentage (%)
19.5%
11.5%
7.1%
77.7%
52.2%
7.8%
26.9%
7.3%
19.8%
45.8%
26.5%
15.6%
19.8%
19.3%
23.7%
12%
8.3%

N
110
65
40
439
295
44
152
41
112
259
150
88
112
109
134
68
47

*AF – Atrial fibrillation, CAD – Coronary Artery Disease, AICD - automatic
internal cardioverter-defibrillator, DM - diabetes mellitus, CKD – Chronic Kidney
Disease, TIA – transient ischemic attack, OSA – obstructive sleep apnea, COPD Chronic obstructive pulmonary disease, History of clots – includes pulmonary
embolism and deep vein thrombosis.

Of the 565 patients included 14.5% (n=82) developed AF during their COVID-19
hospitalization. Of the 82 that developed AF, 28 (34.1%) were identified as new-onset and 54
(65.9%) as having had a history of AF. The mean day on which AF occurrence was noted was
the third day; the range can be seen in Figure 4. Most frequently, AF occurrences happened on
day 1 of admission and likely represented pre-existing AF, either known or unknown by history.
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Figure 4
AF Occurrences During Admission

Admission day of AF occurrences
Of the 565, 55 (9.7%) patients were intubated while 457 (80.9%) utilized non-invasive
ventilatory support (NIV). A FiO2 concentration greater than 50% was needed by 239 (42.3%)
while a FiO2 concentration less than 50% FiO2 was needed by 270 (47.8%).
Several admission laboratory results were collected for this study. Descriptive statistics
on admission laboratory values can be found in Table 2.
Table 2
Admission Laboratory Values in COVID-19 Positive Patients

Ref.
Mean
Median
Range
Min.
Max.

Neutrophils

Lymphocytes

Eosinophils

D-dimer

Creatinine

CRP

Troponin I

2.02-8.40
k/ul
18.06
5.52
6,046.42
0.58
6,047.00

0.67-4.30
k/ul
1.31
0.85
124.32
0.14

0-0.53
k/ul
0.03
0.00
0.80
0.00

<0.05
ug/ml
2.20
1.05
19.85
0.15

0.55-1.02
mg/dl
1.59
1.14
25.95
0.15

<8.0
mg/L
103.21
88.60
424.24
1.76

<0.05
ng/ml
0.46
0.02
42.48
0.02

124.46

0.80

>20.00

26.10

426.00

42.50
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Of the COVID-19 complications, 20 (3.5%) had arterial TE, and 22 (3.9%) had venous
TE. AMS or encephalopathy occurred in 146 (25.8%), other arrhythmias were in 231 (40.9),
stroke 13 (2.3%), acute liver injury 159 (28.1%), acute kidney injury 208 (36.8%), acute cardiac
injury 86 (15.2%), shock 87 (15.4%), respiratory failure 500 (88.5%), and bacterial co-infections
185 (32.7%) occurrences.
Of the COVID-19 therapies available and offered during the study timeline, 464 (82.1%)
participants received corticosteroids, 218 (38.6%) antiviral therapy, 192 (34%) convalescent
plasma, 232(41.1%) antibiotic therapy and 556 (98.4%) pharmacological DVT prophylaxis.
Figure 5
Discharge Disposition

Participant discharge disposition varied greatly. Of the 565, most were discharged home
with self-care 248 (43.9%) while the rest discharged home with home health 84 (14.9%), home
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with hospice 23 (4.1%), skilled nursing facilities (SNF) 96 (17%), left against medical advice 2
(0.4%), transferred to a psychiatric hospital 1 (0.2%), expired on inpatient hospice 8 (1.4%),
expired 101 (17.9%), and transferred to another acute care hospital 2 (0.4%). A visual
representation can be found in Figure 5.
Analysis of Project Research Questions
This DNP scholarly project explores the relationship of AF in COVID-19 positive
patients to determine if patients who have AF occurrences have higher mortality than those that
do not develop AF during their hospitalizations and if they are associated with worse outcomes.
What is the Overall Incidence of AF in COVID-19 Positive Patients Admitted to the Hospital?
To determine the overall incidence of AF in hospitalized COVID-19 positive patients,
frequency calculations were done. The expectation was that 100% of the sample would be
COVID-19 positive, but the incidence of AF occurrences within this sample had to be calculated.
A frequency calculation was run on the patients that had AF occurrences. In all, 82 (14.5%) of
the 565 patients had occurrences of AF on telemetry or ECG tracings during their
hospitalization. New-onset AF occurred in 28 (34.1%) of the 82 patients, while 54 (65.9%) had a
past medical history of AF.
Is There a Difference in the Incidence of AF in COVID-19 Positive Patients Admitted to the
ICU Setting Versus Those in Non-ICU Settings?
To determine the differences in ICU versus non-ICU settings for those who had AF
occur, a chi square goodness-of-fit test was used. Overall, more occurrences of AF were found in
the non-ICU setting. The non-ICU setting (87.5% or 49 of 56) as compared to patients cared for
in the ICU setting (12.5%, 7 of 56), X2 (1, N=56) = 4.29, p = 0.038. However, ICU patients
developed AF at a rate more than double that of non-ICU patients. Of the 29 patients admitted to
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the ICU, 7 (24.1%) developed AF while 22 (75.9%) did not. In the non-ICU settings, 49 (11.2%)
had occurrences of AF during their stay compared to 388 (88.8%) who did not have AF
occurrences. Patients who received both ICU and non-ICU care were excluded from the
statistical analysis.
Are There Differences in LOS and Mortality for COVID-19 Positive Patients Who Have AF
Occurrences Versus Those Who Do Not?
An analysis of the LOS and mortality was calculated in those that had AF occurrences
and those that did not have AF. When examining the LOS in those who had AF occurrences the
LOS was found to be positively skewed. A nonparametric alternative Mann-Whitney U test to
analyze the differences in LOS between those from whom AF occurred and those from whom
did not. The Mann-Whitney U test indicated that hospitalized patients for whom AF occurred
(n=82, mean rank 324) had longer LOS than those who did not have AF occur (n=483, mean
rank 275), U 16,396.5, p= 0.012.
A total of 109 (19.3%) patients expired during their COVID-19 hospitalization. Of
patients who survived their hospitalization with COVID-19, 50 (11%) had AF occurrences and
406 (89%) did not. A higher proportion of patients survived the hospitalization (61%, n=50) that
had AF occurrences than expired (39%, n=32), X2 (1, N=82) = 23.98, p < 0.001.
Because LOS was significantly positively skewed, the nonparametric alternative MannWhitney U was used to determine differences in the LOS for patients with AF in the ICU versus
those not in the ICU. The Mann-Whitney U test indicated that patients with AF occurrences who
were admitted to the ICU (n=7, mean rank 40.43) had a significantly longer length of stay than
those who were admitted to non-ICU setting (n=49, mean rank 26.80) U 88.00, p = 0.037.
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Because mortality was also positively skewed, the nonparametric alternative MannWhitney U was used to determine the mortality with AF occurrences in the ICU versus those not
in the ICU. A total of 56 patients who were admitted to the hospital were placed in ICU or nonICU, but not to both settings, had AF occurrences during their hospitalization. Of these, 18
(32.1%) expired and 38 (67.9%) survived the hospitalization. All 7 patients (100%) with AF in
the ICU setting expired. Of the patients that were admitted to a non-ICU setting, 11 (61.1%)
expired while 38 (77.6) survived; X2 (1, n=49) = 16.88, p <0.001.
What Demographic Factors and Comorbid Conditions are Associated with AF Occurrences?
A simple correlation was done to determine associations of significance with these
demographic scale variables, such as age, BMI, and presenting SaO2, using a nonparametric
alternative, Spearman’s rho. A Spearman’s rho for age and AF occurrences was rho = -.199, p <
0.001. This indicates that the patient with older age tended to have more AF occurrences than
those of younger age and vice versa. There was no significant association found between the
presenting SaO2 on admission and BMI in AF occurrences. A simple correlation was done to
determine associations with these ethnicities and gender, using Pearson’s chi square, however, no
statistical significance was found.
A binary logistic regression analysis to investigate if age and gender were associated with
AF occurrences was conducted. The predictor variables, age and gender, in the logistic
regression analysis were found to contribute to association with AF occurrences; Cox & Snell R2
= .045, Nagelkerke R2 = .081. The unstandardized beta weight for age; B = -.046, SE = 0.830,
Wald = 18.573, Exp B = .955, p < 0.001; gender; B = .510, SE = .253, Wald = 4.046, Exp B =
1.665, p = 0.044; and constant; B = 4.234, SE = 0.830, Wald = 26.020, p < 0.001. Those of an
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older age were more likely to have AF occurrences, those of male gender were also more likely
to have AF occurrences than women.
For comorbid conditions, a chi square test was run to determine the association of
significance with these dichotomous nominal variables. A higher proportion of patients who had
AF occurrences had a history of hyperlipidemia 52 (63.4%) versus those that did not 30 (36.6%);
X2 (1, n=82), 4.824, p=0.031. A higher proportion of patients had occurrences of AF when they
also had a history of hypertension 73 (89%) versus those that did not 9 (11%); X2 (1, n=82),
7.100, p=0.009. A higher proportion of patients had AF occurrences in those who had a history of
AF 53 (64.3%) versus those who did not 29 (35.4%); X2 (1, n=82), 124.800, p < 0.001.
It was determined, through chi square tests, that pre-DM or DM, PM or AICD,
myocardial infarction, stroke or TIA, cancer, OSA, COPD, asthma, and history of clots had no
statistically significant relationship with AF occurrences in COVID-19 positive patients. Several
comorbid conditions were statistically significant, however, were determined to have trivial
relationships in the development of AF occurrences during patient hospitalization. These
included chronic kidney disease, heart failure, CAD, valvular heart disease, and other
arrhythmias.
A binary logistic regression analysis to investigate if a history of AF, hypertension, and
hyperlipidemia were associated with the development of AF occurrences was conducted. A
history of AF was the only significant variable in the final model; Cox and Snell R2 = .162,
Nagelkerke R2 = .288. The unstandardized beta weight for history of AF, B = -2.614, SE = .271,
Wald = 93.321, Exp B = .073, p < 0.001; and constant, B = 2.687, SE = .192, Wald = 196.055,
Exp B = 14.690, p < 0.001.
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How are Typical COVID-19 Treatments Related to AF Occurrences?
COVID-19 treatment variables were coded as dichotomous categorical variables. A
nonparametric alternative Fisher’s exact test was used to determine association/relationship with
AF occurrences.
Of those that received antibiotics during their hospital stay, 47 (20.3%) had AF
occurrences and 185 (79.7%) did not. A higher proportion of patients who developed AF 47
(57.3%) received antibiotics during their COVID-19 hospitalization than those 35 (42.7%) that
did not; X2 (1, n=82) = 10.47, p=0.002. All other typical COVID-19 treatments, such as
antivirals, steroids, convalescent plasma, and pharmacological DVT prophylaxis, were not used
significantly more often with AF occurrences during their COVID-19 hospitalization. The
regression model indicates that antibiotic administration has minimal but significant association
with AF occurrences in hospitalized COVID-19 positive patients (Cox & Snell R2 = .021,
Nagelkerke R2 = .038, p = 0.003).
In the reduced regression model analysis, the use of antibiotics in COVID-19 patients
was added with age and history of AF to analyze association between variables, Cox & Snell R2=
.180, Nagelkerke R2 = .320, p < 0.001.. All variables in the reduced model were positively
associated with occurrences of AF, age, B =-.026, SE=.012, Wald=5.057, Exp B=.974, p=0.025;
history of AF, B =-2.450, SE =.279, Wald=77.340, Exp B=.086, p < 0.001; antibiotics, B = -.711,
SE = .276, Wald=6.637, Exp B=.491, p=0.01; and constant, B =4.800, SE=.856, Wald = 31.449,
Exp B =121.549, p < 0.001.
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Are Admission Laboratory Tests Predictive or Associated with AF Occurrences in COVID-19
Positive Patients?
Simple correlations were done to determine associations of significance, using a
nonparametric Spearman’s rho correlation, between laboratory data and those in which AF
occurs. Lower levels of eosinophils are significantly positively correlated with occurrences of
AF in COVID-19 positive patients; rho=.102, p=0.015. As the serum creatinine and troponin
levels rise, in COVID-19 positive patients, they were likely to have AF occurrences; rho = -.160,
p < 0.001, and rho= –.134, p = 0.015, respectively. Laboratory values that had no statistical
significance or trivial relationships with AF occurrences were neutrophils, lymphocytes, d-dimer,
and CRP.
In a reduced logistic regression model, low eosinophils levels were analyzed and found to
be significantly predictive of AF occurrences, where as serum creatinine and troponin were not
predictive. In a further reduced model and combined with age, history of AF and antibiotic use,
eosinophils were positively correlated with a predictive relationship, Cox & Snell R2 =.191,
Nagelkerke R2 = .340. The unstandardized beta weight for the eosinophils: B = 8.187, SE =
4.048, Wald = 4.048, Exp B =3592.882, p = 0.044; age, B = -.026, SE = .012, Wald = 4.853, Exp
B = .974, p = 0.028; history of atrial fibrillation, B = 2.487, SE = .284, Wald = 76.766, Exp B =
12.021, p < 0.001; antibiotics, B = .807, SE = .281, Wald = 8.221, Exp B = 2.240, p = 0.004; and
constant, B = 1.478, SE = .201, Wald = 54.277, Exp B = 4.384, p < 0.001. This indicates that
those of higher age, with history of AF, antibiotic use and low eosinophils are more likely to
have AF occurrences when they are COVID-19 positive.
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Is There a Pattern in the Course of COVID-19 Illness for AF Onset?
Variables examined were the number of days to AF onset from the admission date, LOS,
and symptom onset. Descriptive statistics were run to calculate the mean, standard deviation,
median, mode, and range of the onset of AF occurrences before admission day. Most (55
[67.1%]) patients with COVID-19 who were hospitalized and had AF occurrences presented
with AF or develop AF on day 1 of admission. The occurrence of AF was otherwise scattered
throughout the hospitalization of COVID-19 patients. Descriptive statistical tests were run and
are located in Table 3.
Descriptive statistics were run on the onset of COVID-19 symptoms started in those who
had AF occurrences and were tracked in days before admission. Of the 82 with AF occurrences,
the minimum days before admission that a COVID-19 positive patient had onset of COVID
symptoms was 1 day and the maximum was 26 days prior.
Table 3
Onset of AF Occurrences in Relation to Hospitalization Day
N=82

MEAN
3.59

MEDIAN
1.00

MODE
1

RANGE
25

MINIMUM MAXIMUM
1
26

Data were analyzed to determine the typical time from COVID-19 symptom onset to
hospitalization. These descriptive statistics indicate that on average patients came to the hospital
for treatment of COVID-19 symptoms on day 7 of symptom onset (see Table 4).
Table 4
Onset of COVID-19 Symptoms in Days
N=81

MEAN
6.57

MEDIAN
7.00

MODE
7

RANGE
41

MINIMUM MAXIMUM
1
42
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A correlation was done to assess the relationship between day AF occurrences during
hospitalization and LOS. A simple scatter plot, shown in Figure 6, shows the distribution of
those that had AF occurrence and LOS. A Spearman’s rho for LOS and AF occurrence (in days
from admission) was rho = 0.57, p < 0.001. This indicates that patients with AF occurrences had
a longer LOS than those without AF occurrences.
Figure 6
Length of Stay by AF Initiation

Are AF Occurrences Associated with an Increased Incidence of COVID-19 Complications?
The complications of COVID-19, as well as AF, were recorded as nominal dichotomous
data. A test of association was done with contingency table and chi-square tests of
significance.
COVID-19 complications of acute kidney injury and arrhythmias, other than AF, had a
proportionately stronger association with the development of AF in the hospital setting as
compared to no AF; X2 (1, n=49) 21.70, p <0.001 and X2 (1, n=51) 18.02, p < 0.001,
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respectively. Other COVID-19 complications; altered mental status or encephalopathy, acute
liver injury, acute cardiac injury, shock, and bacterial co-infections were not significantly
associated with AF occurrence in hospitalized COVID19 positive patients.
A reduced logistic regression model to analyze those COVID-19 complications that were
significant was run. Of the complications tested, acute kidney injury and other arrhythmias were
associated with AF occurrences, Cox & Snell R2 = .062, Nagelkerke R2 = .110. The
unstandardized beta weight for acute kidney injury, B = -1.057, SE = .249, Wald = 18.060, Exp B
= .347, p < 0.001; other arrhythmias, B = -.965, SE = .252, Wald = 14.797, Exp B = .381, p
<0.001; and constant, B = 2.741, SE = .233, Wald = 137.948, Exp B = 15.499, p < 0.001. This
model indicates that the complications of acute kidney injury and arrhythmias are associated
with patients that have AF occurrences while COVID-19 positive.
Are High Levels of Supplemental Oxygen and Invasive Mechanical Ventilation Associated
with AF Occurrences in COVID-19 Positive Patients?
To determine if oxygen delivery methods, such as invasive and non-invasive ventilatory
support (NIV), as well as high oxygen levels, were associated with AF occurrences statistical
analysis using the Fisher’s exact test for these nominal dichotomous variables was used. Of the
patients who used invasive mechanical ventilation while COVID-19 positive, 17 (30.9%) had AF
occurrences while 38 (69.1%) did not have AF occurrences. Of those who had AF occurrences, a
higher proportion of patients did not get intubated 58 (77.3%) versus those that did get intubated
17 (22.7%), X2, (1, n=75) = 12.776, p < 0.001.
Of those who used NIV support, there was a higher proportion who did not have AF
occurrences 395 (87.2%) versus those who did have AF occurrences 58 (12.8%), X2, (1, n=453)
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= 12.776, p < 0.001. Patients who did not get intubated or use NIV support were excluded from
the statistical analysis.
Of those who used greater than 50% FiO2, 49 (20.5%) patients had AF occurrences while
a higher proportion had no AF occurrences 190 (79.5%), X2, (1, n=239) = 11.574, p < 0.001. Of
those that had AF occurrences, a higher proportion utilized greater than 50% FiO2 49 (65.3%)
than those that did not 26 (34.7%), X2, (1, n=75) = 11.574, p < 0.001. There was a subset of the
population that did not use oxygen at all during their stay, but these were excluded in the
statistical analysis.
Following examination of basic relationships, a binary logistic regression analysis to
investigate if intubation, NIV support, or FiO2 levels were associated with AF occurrences was
conducted. The predictor variables, intubation, NIV, and FiO2 levels, in the logistic regression
analysis were found to contribute to association with AF occurrences, Cox & Snell R2 = .033,
Nagelkerke R2 = .058. The unstandardized beta weight for the invasive mechanical ventilation, B
= -.841, SE = .349, Wald = 5.805, Exp B = 3.047, p <0.001; FiO2 greater than 50%, B =-.662, SE
= .280, Wald = 5.579, Exp B = .516, p = 0.018; and constant; B = 2.231, SE = .207, Wald =
116.628, Exp B = .516, p < 0.001. This indicates that patients with invasive mechanical
ventilation and use of FiO2 greater than 50% have higher-odds of having AF occurrences than
those who were not intubated or using less than 50%.
In analysis of the NIV support and less than 50% FiO2, the unstandardized beta weight
for the NIV support, B = -.841, SE = .349, Wald = 5.805, Exp B = .431, p = 0.016, FiO2 less than
50%, B = -.662, SE = .280, Wald = 5.579, Exp B = .516, p = 0.018; and constant, B = 3.734, SE
= .512, Wald = 53.153, Exp B = 41.849, p < 0.001. This indicates that NIV support and use of
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less than 50% FiO2 is associated with lower odds of AF occurrences in those that are COVID-19
positive, Cox & Snell R2 = .033, Nagelkerke R2 = .058.
Additional Statistical Analysis
Considering the amount of data collected, several additional questions could be answered
using the data set as a point of adding to research on COVID-19.
All Predictive Values in AF Occurrences
A binary logistic regression was run on all significant variables; age, gender, history of
AF, eosinophils, antibiotic use, acute kidney injury, arrhythmias other than AF, greater than 50%
FiO2, and intubation. In the logit model age, history of AF, intubation, and acute kidney injury
were statistically significant predictor values. With the variables accounting for 33.9 to 52.8% of
the AF occurrences (Cox & Snell R2 = .339, Nagelkerke R2 = .528), age, B = -.038, SE = .014,
Wald = 6.983, Exp B = .963, p = 0.008; history of AF, B = -2.504, SE = .310, Wald =65.132, Exp
B = .082, p < 0.001; intubation, B = -1.446, SE = .406, Wald = 12.679, Exp B = .236, p < 0.001;
acute kidney injury, B = -1.004, SE = .306, Wald = 10.784, Exp B = .367, p < 0.001; constant, B =
5.992, SE = 1.074, Wald = 31.118, Exp B = 400.216, p < 0.001.
All Predictive Values in Those that Expired
Variables that were determined to be associated and predictive of AF occurrences in
COVID-19 positive patients were also run with those participants that expired. The logit model,
of the expired population, showed that age, intubation and FiO2 greater than 50% were
statistically significant, Cox & Snell R2=.324, Nagelkerke R2=.503. The unstandardized beta
weight for age, B = -.067, SE = .014, Wald = 24.727, Exp B = .935, p < 0.001; intubation, B =
2.849, SE = .428, Wald = 44.294, Exp B = 17.264, p < 0.001; FiO2 greater than 50%, B = 2.793,
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SE = .392, Wald = 50.667, Exp B = 16.327, p < 0.001; and constant; B = -2.966, SE = .999, Wald
= 8.811, Exp B = .052, p = 0.003.
Ethnicity Versus Expired
A binary logistic regression was run to determine if there was a predictive association
between ethnicity and likelihood of expiration. The model of ethnicity was not statistically
predictive of higher odds of death.
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Chapter 5: Discussion
The purpose of this DNP scholarly project was to discover the impact of AF occurrences
in hospitalized COVID-19 patients. Additionally, the scholarly project determined mortality,
LOS and other related factors that correlated with AF occurrences in hospitalized patients.
Discussion of the Research Questions
This scholarly project discovered a 14.5% incidence of AF occurrences in hospitalized
COVID-19 positive. A higher incidence was seen in the non-ICU setting 87.5% than in the ICU
setting 12.5%. Patients who had AF occurrences had longer hospital LOS and were more likely
to survive (61%) their hospitalization than expire (39%). In the ICU setting, higher mortality was
seen as 100% of patients who had AF occurrences expired, correlating with a higher acuity of
overall illness. In the non-ICU setting, patients with AF occurrences were more likely to survive
(77.5%) than expire (22.4%).
COVID-19 positive patients with AF occurrences were more likely to be older and male
gender. The binary logit models showed that a history of AF, antibiotics, low levels of
eosinophils, and complications of acute kidney injury and other arrhythmias (i.e. other than AF)
were associated with AF occurrences in hospitalized COVID-19 positive patients. Patients who
had AF occurrences were more likely to have them on day 1 (67.1%) of admission. Most often in
patients with AF occurrences, patients presented to the hospital on day 7 after the onset of their
COVID-19 symptoms. In binary logistic regression, invasive mechanical ventilation and greater
than 50% FiO2 were associated with a higher odd of having AF occurrences.
A final binary logistic regression was run to analyze all significant variables in a single
model. Of those significant variables, age, history of AF, invasive mechanical ventilation, and
acute kidney injury were found to be associated with the AF occurrences in hospitalized COVID-
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19 positive patients. In the following sections, results from this scholarly project are compared
and contrasted to results in known literature.
What is the Overall Incidence of AF in COVID-19 Positive Patients Admitted to the Hospital?
Of the 565 participants in this study, 82 (14.5%) patients had AF occurrences during
hospitalization. Bhatla et al. (2020) reported 25 of 700 (3.5%) AF occurrences. Sala et al. (2020)
reported 8 of 132 (6%) participants having AF occurrences. Sala then further categorized the
subtypes of AF; 4 (3%) chronic AF and 4 (3%) new-onset AF. Similarly, Fernando et al. (2020)
reported 10.3% of 1,541 patients had new-onset AF in the ICU. Other literature was less specific
about types of arrhythmias. Angeli et al. (2020) reported that 6% of their 50 patients had AF
occurrences. Du et al. (2020) reported that 50 of 85 (58.8%) developed an arrhythmia during
their hospitalization. Similarly, Wang et al. (2020) determined that 23 (16.7%) had arrhythmias
occur. Neither Du et al. (2020) or Wang et al. (2020) further specified types of arrhythmia that
occurred in their research.
Overall, the literature showed a 3% to 14.6% incidence of AF occurrences in hospitalized
COVID-19 positive patients. This scholarly project reports 14.5% of hospitalized COVID-19
positive patients had AF occurrences, which is consistent with the incidence reported in other
studies. The smaller percentages of AF incidence are mostly from non-American studies and
may not represent an accurate rate of AF occurrences in COVID-19 positive patients in the U.S.
The closest incidence seen in prior literature in the U.S. is a study in New York showing an
incidence of AF in 154 of 1,053 (14.6%) in COVID-19 positive patients (Peltzer et al., 2020).
Additionally, this scholarly project found that new-onset AF or previously undetected AF
occurred in 28 of 82 (34.1%) of those that were COVID-19 positive, which is more than reported
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by Sala et al. (2020). Thus far, no other studies have reported the incidence rate of new-onset AF
occurrences in COVID-19 positive patients.
Of the 565 participants in this study, 110 (19.5%) in the sample had a history of AF
whereas Bhatla et al. (2020) reported 39 of 700 (6%). The difference in these percentages could
be accounted for by a shorter timeline, this study being conducted later in the pandemic, and/or
differences in demographic factors such as the location of study facility, ethnicity, or age. A
single snapshot study in Milan Italy reported that 16 of 132 (12%) had a history of AF (Sala et
al., 2020). Incardi et al. (2020) reported 19 of 99 (19%) and Lala et al. (2020) reported 206 of
2,736 (7.5%) with a history of AF.
In a non-COVID-19 study, Fernando et al. (2020) reported that 12.3% of 2,105 patients
had a history of AF before their ICU admission. Peltzer et al. (2020) reported the highest history
of AF in those that had AF/AFL occurrences 65 of 166 (39.2%), p < 0.001. 146 (13.9%) were
still hospitalized after the study ended so the study may not have captured the entire population
with AF occurrences and AF history.
Overall the literature shows that COVID-19 positive patients with a prior history of AF
ranges from 6% to 39.2%. This scholarly project reports 19.5% had a prior history of AF, which
is consistent with known prevalence.
Is There a Difference in the Incidence of AF in COVID-19 Positive Patients Admitted to the
ICU Versus Those in Non-ICU Setting?
There was a higher proportion of AF occurrences in the non-ICU setting (87%) than in
the ICU (12.5%) in this scholarly project. Wang et al. (2020) reported the opposite of what was
found in this scholarly project, although their results were not specific to AF. Of the 138 in their
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sample, 16 of 23 (44.4%) of the patients experienced arrhythmias in the ICU versus 7 (6.9%) in
the non-ICU setting (Wang et al., 2020). The data collected in this study also showed that they
had 61.6% of their sample remaining in the hospital at the conclusion of the study, which could
account for the lower rate of arrhythmias seen in the non-ICU setting. This scholarly project had
no patients remaining hospitalized at the conclusion of the study. At times of high admission
volumes, hospitals with limited available beds in ICU sometimes would keep patients in nonICU wards even though their acuity met the standards of the ICU. Many hospitals have had to
turn their non-ICU settings into step-down or ICU level acuity by keeping patients on maximum
levels of both vapotherm and non-rebreather masks. Under normal circumstances, those types of
patients would be cared for in the ICU.
Chen et al. (2020b) stratified their COVID-19 positive patients as “severe” and “critical”.
Critical cases were characterized with any of the following: respiratory failure with an artificial
airway requiring mechanical ventilation, shock, or combining failure of other organs in the ICU.
Severe cases were characterized with one of the following: respiratory distress (RR > 30
per/min), peripheral oxygen saturation < 93% at resting state, or arterial partial pressure
(PaO2)/FiO2 <= 300mmHg. These findings could be compared to the ICU setting because the
characteristics of “critical” are nearly identical to ICU care. Atrial fibrillation was rare in their
study, reporting 1 critical case in 54 (1.8%) with AF occurrences. No AF occurrences were
reported in the severe category.
Of those in the non-ICU setting, Sala et al. (2020) reported 8 of 132 (6%) had AF
occurrences. There are limitations to this study as there is a lack of comparison to the ICU setting
and the study timeline is a single-day snapshot which makes it difficult to capture the accurate
incidence in the non-ICU due to the paroxysmal nature of AF.
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Overall the literature shows AF occurrences in the ICU from 1.8% to 44.9%. As for the
non-ICU setting, literature reports range from 6% to 6.9%. In this scholarly project, 12.5% had
AF occurrences in the ICU which is within the known range. On the other hand, 87% in the nonICU setting was significantly higher than other reported ranges. The reported ranges for non-ICU
settings have their limitations; single-day study design, small sample sizes, and lack of ICU
capacity.
Are there Differences in Length of Stay and Mortality for COVID-19 Patients Admitted to the
Hospital Who Have AF occurrences Versus Those Who Do Not?
Bhatla et al. (2020) associated AF with in-hospital mortality (OR 6.73; 95% CI; 2.5217.98) but noted this to be not statistically significant after multivariate analysis. Incardi et al.
(2020) reported that COVID-19 positive patients who had a history of cardiac disease had
significantly higher mortality than those with no history of cardiac disease (35.8% vs. 15.2%;
log-rank, p = 0.019; relative risk 2.35; 95% CI; 1.08-5.09). Even after controlling for patients
who declined invasive mechanical ventilation due to comorbid problems or age, the mortality
rate of patients with a history of cardiac disease remained high (26% versus 9%; p = 0.0039).
Peltzer et al. (2020) reported mortality to be significantly higher in those with AF or atrial flutter
compared to those without (39.2% vs. 13.4%), p < 0.001, but, did not do a multivariate analysis
to determine if AF occurrences were a predictor for mortality in COVID-19 patients.
A study in northern Italy reported that patients with a history of cardiac disease had a
LOS of (median=11.8) versus (median=10.8) days without a history of cardiac disease, p = 0.48
(Incardi et al., 2020). Fernando et al. (2020) reported the LOS among ICU COVID-19 patients
who had new onset AF (median 14, 8-29 days) versus those without AF (median 12, 4-25 days),
p < 0.001.

60
Within this scholarly project, we determined those who had AF occurrences (median 6,
1-60 days) had longer LOS than those that did not have AF occur (median 4, 1-36 days), U
16,396.5, p = 0.012. Of those COVID-19 positive patients who survived their hospitalization, 50
(11%) had AF occurrences while 406 (89%) did not. Overall, a higher proportion of patients who
had AF occurrences survived than expired, which is consistent with known mortality rates of AF
and COVID-19. Cardiovascular history puts patients at higher risk of death when COVID-19
positive than just AF alone.
Are There Differences in Length of Stay and Mortality for COVID-19 Positive Patients Who
Have AF Occurrences in ICU Versus Non-ICU Settings?
Bhatla et al. (2020) reported a more than 10-fold higher acute mortality in the ICU
compared to those admitted to the non-ICU, further analysis showed AF, bradyarrhythmias,
and/or NSVT events were not independently associated with acute in-hospital mortality. Shaver
et al. (2020) reported that 236 of 1,770 (13%) patients had any type of AF occurrences in the
ICU and were further associated with higher mortality. Of those 1,770 patients, 71 (30%) died
with AF occurrences compared to 265 (17%) with no AF occurrences, p <0.001 (Shaver, et al.,
2020). After logistic regression, any type of AF occurrences was found to be significantly
associated with increase mortality, (OR 1.62, 95% CI; 1.14-2.29, p = 0.007).
Overall this scholarly project found that 56 patients had AF occurrences during their
hospitalization. Of those patients, the majority survived 38 (67.9%) to discharge. In the ICU, 7
(100%) of the patients with AF occurrences died, which is a much higher percentage than Shaver
et al. (2020) reported (30%). Those in the non-ICU setting had 11 (22.4%) expire while 38
(77.6%) survived; X2 (1, n=49) = 16.88, p < 0.001. Shaver et al. did not have any comparison of
mortality in patients that had AF occurrences in the non-ICU settings.

61
In the general population, Fernando et al. (2020) reported that in the ICU patients with
new-onset AF (median 14, 8-29 days) had a longer length of stay versus those without AF
(median 12, 4-25 days), p <0.001. Ultimately there were very few studies that investigated AF
occurrences in COVID-19 positive patients that looked at LOS in the ICU versus non-ICU
settings. This scholarly project reports that patients had significantly longer LOS in the ICU
(median 11, 2-42 days) compared to those admitted to a non-ICU setting (median 4, 1-19 days)
U 88.00, p = 0.037. Shaver et al. (2020) reported that those in the ICU with AF had LOS of
(median 14, 9-24 days) versus those that had no AF occurrences (median 11, 6-19 days), p =
0.001.
What Demographic Factors and Comorbid Conditions are Associated with Development of
AF?
Bhatla et al. (2020) reported that every one year increase in age was associated with an
increased incidence of AF (OR 1.06; 95% CI; 1.04-1.09). Even after multivariate analysis age
was independently associated with the incidence of AF (OR 1.05; 95% CI; 1.02-1.09). However,
there was no association between sex, race, BMI, diabetes, hypertension, and CKD in the
incidence of any arrhythmia observed in univariate or multivariate analysis (Bhatla et al., 2020).
This scholarly project showed that those of an older age tended to have more AF
occurrences than younger patients. There was no significant association between presenting
SaO2 on admission, ethnicity, or BMI in AF occurrences.
Bhatla et al. (2020), in univariate analysis, reported an association with incidence of AF
and heart failure (OR 5.61; 95% CI; 2.37-13.25). After multivariate analysis, heart failure was
not found to be independently associated with AF incidence. Of note, a history of AF was not
collected in this study. Sala et al. (2020) reported that those who developed AF occurrences had
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at least one comorbid condition. Peltzer et al. (2020) reported that after a multivariable
regression analysis a history of AF and renal disease were the only comorbid conditions
independently associated with AF and atrial flutter.
This scholarly project found that a higher proportion of patients with AF occurrences had
a history of hyperlipidemia, hypertension, and a history of AF. After reduced logistic regression
analysis, a history of AF was found to be associated with the development of AF occurrences
while COVID-19 positive. No association of heart failure to AF occurrences was found.
While there was very little literature correlating comorbid conditions to AF occurrences,
other COVID-19 literature did show association to comorbid conditions with cardiac injury. Shi
et al. (2020) reported that patients with cardiac injury were more likely to have comorbidities,
including hypertension (49 [59.8%] vs. 78 [23.4%]), chronic heart disease (24 [29.3%] vs. 20
[6%]), chronic heart failure (12 [14.6%] vs. 5 [1.5%]), and cancer (7 [8.5%] vs. 2 [0.6%]), all p
< 0.001. Shi reported these comorbid conditions with slightly less statistical significance;
diabetes (20 [24.4%] vs. 40 [12.0]), p = 0.008; and COPD (12 [2.9%] vs. 6 [7.3%]), p = 0.02.
Lala et al. (2020) reported that patients who had myocardial injury had associated comorbid
problems such as atrial fibrillation, coronary artery disease, chronic kidney disease, COPD,
diabetes, heart failure, and hypertension, all p < 0.001. Neither Shi nor Lala analyzed by using
regression to determine if these comorbid conditions were independently associated with the
development of the cardiac injury.
How are Typical COVID-19 Treatments Related to the Development of AF?
Shi et al. (2020) reported that glucocorticoids, intravenous immunoglobulin therapy, and
antibiotic therapy were statistically associated with cardiac injury in COVID-19 positive patients,
p < 0.001. Peltzer et al. (2020) reported that hydroxychloroquine (p = 0.032), steroids (p <
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0.001), and IL-6 inhibitors (p = 0.043) are associated in the development of AF or atrial flutter
(AFL) occurrences in COVID-19 positive patients.
In this scholarly project, of those who received antibiotics during hospitalization 47
(20.3%) had AF occurrences and 185 (79.7%) did not. A higher proportion of those who had AF
occurrences 47 (57.3%) received antibiotics during their COVID-19 hospitalization versus those
who did not 35 (42.7%); X2 (1, n=82) = 10.47, p=0.002. Specific medications were not
subcategorized within the typical COVID-19 treatments in this scholarly project. COVID-19, as
are many viral infections, is associated with secondary bacterial infections and could explain
why a majority of patients had received antibiotics during their COVID-19 hospitalization who
had AF occurrences, however, this is not a causal relationship. A binary multivariate analysis
indicated that antibiotics were associated with an increased odds of AF occurrences in COVID19 positive patients. All other typical COVID-19 treatment including steroids, antivirals,
convalescent plasma, and DVT prophylaxis were not statistically related to AF occurrences in
hospitalized COVID-19 positive patients.
Are there Laboratory Tests Predictive or Associated with AF occurrences in COVID-19
Positive Patients?
Less specific to AF occurrences, Du et al. (2020) reported that patients who were
COVID-19 positive had an eosinophil count (mean=0.013, SD = 0.025) below the normal range
(0.02-0.52 x 109 cells/L). Du et al. (2020) surmised that the low eosinophils were correlated to
the high viral load of SARS-CoV-2, which triggers eosinophil granule protein consumption since
eosinophil granule proteins neutralized viruses.
Du et al. (2020) reported renal impairment in 48 (56.5%) COVID-19 positive patients
with elevation of creatinine and BUN (mean 113.73, SD 149-70). Of those with cardiac disease
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and who were COVID-19 positive, Inciardi et al. (2020) reported higher elevation in creatinine
versus non-cardiac patients (1.1 vs. 1.0 mg/dl; p = 0.037). Unfortunately, Incardi et al. (2020) did
not analyze eosinophil levels within the study. Lala et al. (2020) reported median levels of
creatinine (0.87 vs. 1.30) in those without cardiovascular risk factors versus those with
cardiovascular disease. Lala defined cardiovascular disease as CAD, AF, and HF. Troponin I
concentrations greater than 0.09 ng/dl were associated with a more pronounced risk of death.
(Adjusted HR: 3.03; 95% CI; 2.42-3.80).
Incardi et al. (2020) reported nearly double the level of high sensitivity troponin I in
cardiac versus non-cardiac patients (34 vs. 16, p < 0.001), respectively. Chen et al. (2020b)
reported that those with elevated troponin I (median 0.29 vs. 0.014), CK-MB, and myoglobin
were significantly higher in their critical group compared to the severe group (p < 0.01).
However, after multi-factor logistic regression was done troponin was no longer significant in
predicting the severity of COVID-19. Shi et al. (2020) reported patients who had elevations in
high-sensitivity troponin I (median=0.19 vs. <0.006; p < 0.001) and serum creatinine
(median=1.15 vs. 0.64; p < 0.001) in those with and without cardiac injury while COVID-19
positive, respectively. Of patients who had ECG changes, Angeli et al. (2020) reported that
creatinine and high-sensitivity troponin I were not significantly different between those with
ECG changes compared to those without ECG changes.
Peltzer et al. (2020) reported that COVID-19 positive patients who had AF or atrial
flutter occurrences had statistically significant median elevations in labs versus those who had no
AF or atrial flutter; troponin I (0.13 vs. 0), CRP (31.8 vs. 17.5), BNP (225 vs 48), D-dimer (3261
vs. 1139), ESR (103 vs.86), and ferritin (1449 vs. 1011), all p. < 0.001.
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In this scholarly project, low eosinophil levels (mean = 0.028, 0.076) and elevated
troponin (mean = 0.461, SD = 3.333) and creatinine levels (mean = 1.593, SD = 1.889) were
associated with AF occurrences in COVID-19 positive patients. After reduced logistic
regression, only low eosinophilia levels were associated with AF occurrences in COVID-19
positive patients. This finding is consistent with what was presented in Du et al. (2020). All other
studies that were reviewed except one did not use multivariable logistic regression for the
prediction of labs.
Is There a Pattern in the Course of COVID-19 Illness for AF onset?
In this scholarly project, the number of days to AF onset from admission date were
examined. The majority (67.1%) of patients with COVID-19 who were hospitalized and had AF
occurrences presented with AF or developed AF on day 1 of admission. The maximum days of
AF onset from admission were 26 days. No other studies looked at this variable specifically in
those with AF.
In this scholarly project, patients with AF occurrences came to the hospital for treatment
of COVID-19 symptoms on day 7 after symptom onset. This is consistent with the onset of
symptoms to hospital admission of 7 days (median) (Wang et al., 2020). Wang et al. (2020)
further determined that those in the ICU had a longer onset of symptoms to hospital admission
that was statistically significant (median 8, 4.5-10 days) versus non-ICU setting (median 6, 3-7
days), p = 0.009. Du et al. (2020) reported the mean of 10.1 days of these 85 fatal COVID-19
cases, however, these were not specific to those that had AF. This could indicate that those who
delay seeking medical attention could have worse outcomes than those who seek medical
attention earlier. Shi et al. (2020) reported that the time from symptoms onset to admission was
not statistically significant between those with (median 10, 1-30 days) and without cardiac injury

66
(median 10, 1-28 days). In COVID-19 positive patients with AF occurrences, patients had a
longer LOS (onset of symptoms) than those without AF occurrences.
Is the Development of AF Associated with an Increased Incidence of COVID-19
Complications?
Peltzer et al. (2020) reported that there was a statistically higher proportion of patients
who had AF/AFL and who had COVID-19 complications such as ICU admission, vasopressors
therapy, invasive and non-invasive mechanical ventilation, bacteremia, stroke,/TIA, CRRT, and
death. When comparing those with cardiac disease who survived versus died, 11 (57.9%)
experienced ARDS at a statistically higher proportion than those that survived 1 (2.9%), p <
0.001, (Inciardi et al., 2020). ARDS, acute kidney injury, electrolyte disturbances,
hyperproteinemia, and coagulation disorders were statistically higher in those that had a cardiac
injury than in those without (Shi et al., 2020).
In this scholarly project, complications of acute kidney injury and other arrhythmias,
other than AF, had a proportionally stronger association with AF occurrences in the hospital
setting even after multivariate analysis; X2 (1, n=49) 21.70, p < 0.001 and X2 (1, n=51 18.02, p <
0.001, respectively.
Are High Levels of Oxygen and Invasive Mechanical Ventilation Associated with AF
occurrences in COVID-19 Positive Patients?
In the 166 COVID-19 positive patients who had occurrences of AF or atrial flutter,
60.2% used invasive mechanical ventilation compared to those that did not have AF or atrial
flutter 25.6%, p < 0.001 (Peltzer, et al., 2020). Of 85 fatal COVID-19 patients, Du et al. (2020)
reported 57 (67.1%) used oxygen therapy, NIV 61 (71.8%), and invasive mechanical ventilation
18 (21.2%). A higher percentage of patients died who used NIV than any other form of treatment
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for respiratory failure. Patients who died using NIV may or may not have been offered more
invasive forms of respiratory treatment, but declined due to age, comorbid conditions,
preferences, or other factors.
Incardi et al. (2020) reported that COVID-19 positive patients stratified by concomitant
cardiac disease used greater than or equal to 50% FiO2. A higher proportion of patients with
concomitant cardiac disease (29 [54.7%]) used greater than or equal to 50% FiO2 versus those
without cardiac disease (18[43.7%]) but was not found to be statistically significant. Shi et al.
(2020) reported that COVID-19 patients with cardiac injury used oxygen inhalation (31%), NIV
(46.3%), and invasive mechanical ventilation (22%), all p < 0.001. NIV 46.3% and invasive
mechanical ventilation 22% occurred at a higher proportion in those with cardiac injury while
oxygen therapy did not (Shi et al., 2020).
Of the 138 COVID-19 positive patients, these treatments were statistically correlated
with admission to the ICU; 11% received high-flow oxygen, 41.7% NIV, and 47.2% invasive
mechanical ventilation, all p < 0.001(Wang et al., 2020). Of 99 COVID-19 positive patients,
76% used oxygen therapy, 13% used NIV and 4% used invasive mechanical ventilation (Chen et
al., 2020a).
Guan et al. (2020) reported differences in those who were categorized as severe and nonsevere cases in COVID-19 positive patients in regards to their use of oxygen therapy, NIV, and
invasive mechanical ventilation. Of the 1,099 COVID-19 positive patients, 41.3% of patients
used oxygen therapy, 5.1% used NIV, and 2.3% used invasive mechanical ventilation. The use of
oxygen therapy was higher in severe cases (71.1%) than non-severe cases (35.7%).
A New York prospective observational case series followed patients from March 1
through April 4, 2020, and reported the outcomes of patients who received mechanical
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ventilation stratified by age group; <18, 18-65, and >65 (Richardson et al., 2020). In those who
were > 65 years of age with COVID-19, 0.7% were discharged alive, 41.8% died and 25.4% of
patients remained hospitalized. In those between the ages of 18-65, 2.4% discharged alive,
79.9% died, and 28.7% remained hospitalized. In those < 18 years old, 28.6 patients remain
hospitalized, as no patients died or had been were discharged alive. In the general population,
invasive mechanical ventilation and NIV are not statistically associated with the development of
new-onset AF versus no AF (Fernando et al., 2020).
In this scholarly project, patients who had AF occurrences used invasive mechanical
ventilation 17 of 55 (30.9%) and/or used greater than 50% FiO2 49 of 239 (20.5%). In binary
logistic regression, patients who used invasive mechanical ventilation and greater than 50% FiO2
had higher odds of AF occurrences.
Observations
This study showed that AF is associated with multiple factors and with poor outcomes in
many disease processes including but limited to COVID-19. The majority of the outcomes are in
line with what was already known about the incidence of AF, however, there were several new
findings that have never been investigated before.
It’s reassuring that 87% of patients who have AF occurrences while COVID-19 positive
in the non-ICU setting survived. It’s worrisome that 100% of all the ICU patients with AF
occurrences died.
Limitations
A single-center data collection limited the number of patients available for participation
in the study. Although the use of a single-center may be somewhat limiting in generalizability to

69
other institutions, the sample was large. A specified timeframe limited the volume of patients but
still provide adequate sample size and additionally provided for treatment consistency.
A retrospective design created limitations in data collection because clinicians do not
document for researchers, which can inherently and unknowingly cause holes in data collection.
A new EHR, Epic was instituted on November 4, 2019, at the study facility and so there
is a possibility that the clinicians’ unknowingly creating gaps in the medical record by
documenting information in different places than intended. Delaying data collection to later in
2020 hopefully attenuated some of the learning curve and improved data collection by
minimizing gaps in the EHR as clinicians, nurses and patient care staff learn to use the new EHR
program. Dichotomous nominal variables make for easier data collection. However, these types
of variables also limit the type of statistical tests that can be used in statistical analysis.
The main non-ICU COVID-19 unit did not have a dedicated ECG monitor technician,
which could have led to the under detection of arrhythmias in some cases. As cases increased in
the fall of 2020 and increased capacity was needed and an additional COVID-19 unit was opened
which had centralized telemetry monitoring like the majority of the hospital. This may have
limited the data for comparing non-ICU to ICU. Time was not a factor in the collection of the
data as the design of the study was not dependent on any time limitations.
Implications for Further Research
To adequately answer questions about an inferential relationship between AF and
COVID-19 further prospective studies and random controlled trials will need to be conducted to
determine if there is a causal relationship or association between AF and COVID-19. Within a
random controlled trial or prospective study cofounding factors could be adjusted and treatments
controlled so that researchers could determine if there exists causal relationships.
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The project should be replicated in a different sample that is more ethnically diverse, as
this sample majority was 77% white. With a more diverse sample, these results could be vastly
different and demonstrate a need to tailor treatment protocols to those results. A more diverse
sample could mean a more generalizable application nationally as well.
Further research is needed to define treatment protocols in these smaller populations, to
improve mortality and outcomes. A post-discharge follow-up to determine mortality at thirty
day, six month, and one year mortality could help determine long-term outcomes for patients
with AF occurrences. The impact of COVID-19 vaccines on AF occurrences in COVID-19
positive patients is yet to be determined. Whether new COVID-19 treatments or AF treatments
have an effect on morbidity, mortality and LOS within this population will need further research.
Application to Practice
In general, COVID-19 patients with a history of AF, older age, and of the male gender
are more likely to have AF occurrences during their hospital stay. In the ICU setting, AF
occurrences should signal to clinicians of an increasing mortality rate and LOS. Additionally,
special treatment protocols need to be explored for COVID-19 patients with AF who are in the
ICU. These might focus on more intentional rate control or rhythm control in addition to other
COVID-19 therapies. Or there may be a need for better inotropic support of these patients with
AF and COVID-19. Furthermore, clinicians need to consider the anti-platelet and anticoagulant
status and therapies that are most effective in this population.
Conclusion
The overall aim of this DNP project was to describe relationships between AF and
COVID-19. This scholarly project has brought about observational data on COVID-19 and the
relationship between COVID-19 and AF, for which to date very little is known. This topic
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continues to be very important as COVID-19 and its variants continue to present critical
challenges to patient care across the lifespan.
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November 19, 2020
Principal Investigator: Diana LaVerne Taylor
Research Project: A Fib (AF) in COVID-19 Patients
IRB Tracking Number: 2020-2021-050
Dear Diana,
It is a delight to inform you that your research protocol titled “A Fib (AF) in COVID-19 Patients“ has been
approved by the Southern Adventist University Institutional Research Board according to the proposal. You are now
authorized to proceed with the project as outlined. This approval expires May 31, 2021.
As a principal researcher, you have the ultimate responsibility for the conduct of the study, adherence to ethical
standards, and protection of the rights and welfare of human participants. As you proceed with your research, you
are expected to:
1) Conduct the study according to the approved protocol.
2) Make no changes to the approved study. If changes are necessary, proceed with one of the following:
a) For minor changes to this protocol, please notify IRB by submitting an IRB Form B and proceed after
its approval.
b) For substantial changes, submit a new IRB Form A and proceed after its approval.
3) Use the approved procedure and forms for obtaining informed consent and data.
4) Promptly report any significant adverse events to the IRB within five working days of occurrence using an
Adverse Report Form.
All forms must be submitted to irb@southern.edu.
We wish you many blessings as you move forward with this study and look forward to reading your findings when
they are ready. If there is anything else we can do to assist you with this research study, please contact us.
Always in His service,

Responsibility – Input – Strategic – Learner – Achiever
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FWA Number: FWA 00019514 OHRP
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TO:
PROJECT TITLE:
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REVIEW TYPE:
REVIEW CATEGORY:

February 14, 2021
Diana Taylor, BSN
[1663953-1] COVID-19 & Atrial Fibrillation
New Project
ACTIVE
APPROVED
February 14, 2021
February 13, 2022
Expedited Review
Expedited review category #5

Thank you for your submission to the Catholic Health Initiatives Institute for Research and Innovation Institutional
Review Board (CHIRB). The CHIRB has APPROVED your submission. All research must be conducted in
accordance with this approved submission.
This study meets the criteria for a waiver of consent for the entire study according to federal regulations pertaining to
human subject research.
Please note that it is your responsibility to obtain any additional local institutional or departmental required
approvals prior to initiating your study.
Any revision to previously approved materials must be reviewed and approved by the CHIRB prior to implementation,
except when necessary to eliminate apparent immediate hazards to the subject. If, during the course of the research,
it becomes necessary to modify the study to eliminate apparent immediate hazards to research participants, you are
required to notify the IRB by submitting a study modification.
Please submit modifications through IRBNet, and use the appropriate revision forms for this procedure.
The CHIRB requires prompt reporting (within 10 business days of discovery) of events that are Unanticipated
Problems regardless of whether the event occurred at the local study site (internal UAP) or at another participating
study site (external UAP). Unanticipated Problems are 1) unanticipated AND
2)
serious or life-threatening or potential for increased risk AND 3) possibly or definitely related to the protocol,
as determined by the investigator. Unanticipated deaths that meet these 3 criteria must be reported to the CHIRB
within 24 hours of discovery. Events that are not Unanticipated Problems may be reported to the CHIRB in summary
form at the time of continuing review. All FDA and sponsor reporting requirements should also be followed.
All major protocol departures regarding this study must also be reported within 10 business days to this office. Major
protocol departures are events that impact the risk and benefit of the research; may impact subject safety, affect the
integrity of research data and/or affect a subject's willingness to participate in the research. All minor protocol
departures can be reported at the time of continuing review.
Periodic Review and Study Closure: Your CHIRB CHECK-IN REPORT is due on February 13, 2022 and should be
submitted in IRBNet 30 days prior to this 'next report due date.' The CHIRB staff will send reminder emails for
completing this CHIRB CHECK-IN REPORT, but the investigator is required to submit the CHIRB CHECK-IN
REPORT on time. The CHIRB CHECK-IN REPORT is also required to be submitted when the research has been
completed. Please note that all research records must be
retained for a minimum of three years after the completion of the project. Consent forms, including those for optional
procedures, or other study documents pertaining to HIPAA, must be maintained for at least 6 years after the end of
the study.
The following documents have been approved or noted as part of this approval:
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Application Form - Research Routing Form - CHI Memorial (UPDATED: 11/19/2020)

•

CHI - Research Application - CHI - Research Application (UPDATED: 02/7/2021)

•

Cover Sheet - Cover Letter_CHIIRB.docx (UPDATED: 11/23/2020)

•

Other - IRB Approval Letter - Southern Adventist University (UPDATED: 11/19/2020)

•

Protocol - SAU IRB_final application with protocol (UPDATED: 11/23/2020)

If you have any questions at any time, please feel free to contact the CHIRB at 1-844-626-2299 or
CHIRB@CatholicHealth.net. Please include your project title and reference number in all correspondence with the
CHIRB so that we can best assist you.
Thank you.
This letter has been electronically signed in accordance with all applicable regulations, and a copy is retained within Catholic Health
Initiatives Institute for Research and Innovation Institutional Review Board (CHIRB)'s records.
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Appendix C
Data Collection Variables
Descriptive Data
Age (#)
Ethnicity
Gender (M, F, Other)
BMI (#)
Weight (kg)
Height (cm)
Presenting oxygenation (%)
Onset of symptoms to admission
Admission Lab Tests
D-dimer (#)
Creatinine, serum (#)
Lymphocyte (#)
Neutrophil (#)
Eosinophil (#)
C-reactive protein (#)
Troponin I (#)
Complications (Y/N)
Arterial TE
Venous TE
AMS/Encephalopathy
Shock
Acute kidney injury
Acute cardiac injury
Respiratory Failure
Bacterial Co-infection

Comorbid Conditions (Y/N)
Hx of Atrial Fibrillation
Hypertension
Hyperlipidemia
Heart Attack
Coronary Artery Disease
Other Arrhythmias
Pacemaker or AICD
Heart Failure
Diabetes Mellitus or Pre-DM
Chronic Kidney Disease
Stroke or TIA
Cancer
Obstructive Sleep Apnea
COPD
Valvular Heart Disease
History of Clots (DVT or PE)
Asthma
COVID Treatments (Y/N)
Steroids
Anti-virals
Convalescent Plasma
Antibiotics
Pharmacological
DVT Prophylaxis

Admission Location
ICU (Y/N)
Non-ICU (Y/N)
LOS (#, days)
Discharge Disposition (Y/N)
Home Self Care
Home with Home Health
Home on Hospice
Skilled Nursing Facility
Transfer to Acute Care Facility
Expired
Expired on Inpatient Hospice
Psychiatric Hospital
Left Against Medical Advice
AF occurrences
AF occurrences (Y/N)
Day of AF start (#, days)
Pulmonary Intervention (Y/N)
Invasive mechanical ventilation
NIV* support
FiO2 > 50%
FiO2 < 50%

(*NIV - non-invasive ventilatory support: nasal cannula non-rebreather, simple mask, oxymizer,
bipap/cpap, vapotherm, or high-flow).
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Appendix D
EOP SLO Synthesis
Cultural Competence
A. Your identified clinical problem and how do you think you would be able to show
competency with this Scholarly Project?
This scholarly project will include all participants of any ethnic background that present to
the hospital with COVID-19 symptoms and that are admitted to the hospital. Those that are
older than 18 years and younger than 89 years will be included. Those younger than 18 and over
89 years old will be excluded because they are a protected class of persons within research.
B. Is this application of your clinical problem to the EOP-SLO easy or difficult to think
about competency?
I think it is easy to apply cultural competency to this scholarly project on AF occurrences in
COVID-19 patients, however, anyone involved in the project must identify and set aside biases
and assumptions when conducting research. Some biases and assumptions may not be true and
can alter the desired outcomes of research.
C. Looking at the comparison table - how similar or different are the EOP SLOs to its DNP
Essential (as seen on the table)?
SAU Son incorporates a spiritual aspect into cultural competency. The other entities rely
more on scientific knowledge to support their evidence. Being culturally competent does
incorporate the patient’s spiritual beliefs and practices, and keeps those in mind when adjusting
the patient’s treatment plans. The, Six Aims, focused on providing steady quality care without
having the personal characteristics to change the high level of care provided.
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Evidence-Based Practice
A. Your identified clinical problem and how do you think you would be able to show
competency with this Scholarly Project?
This EOP SLO is probably the easiest to utilize as it correlates with finding evidence
based on current literature on the topic. There is no intervention used in the design of this
scholarly project, however, there is heavy use of informatics within the retrospective descriptive
design.
B. Is this application of your clinical problem to the EOP-SLO easy or difficult to think
about competency? Explain
Applying evidence-based practice research to the scholarly project is easy because this
project must be supported by rigorous peer-reviewed research to be valid and relevant for use in
publication. Without these standards in place, the scholarly project has little value when
attempting to disseminate evidence.
C. Looking at the comparison table - how similar or different are the EOP SLOs to its DNP
Essential (as seen on the table)?
This is only essential this is pretty much the same across the board for all 4
academic/professional entities. It’s founded in scientific-based knowledge that is applied to
clinical practice.
Health Promotion:
A. Your identified clinical problem and how do you think you would be able to show
competency with this Scholarly Project?
Identifying risk factors for both COVID-19 and AF are integral in preventing disabling
sequelae, which is considered tertiary prevention within health promotion. This scholarly project

84
is the first step in determining the prevalence of disease that exists in hospitalized COVID-19
patient population. Through this research, more questions can be asked and further research can
answer these questions about details that affect primary, secondary, and tertiary prevention of AF
within COVID-19 patients.
B. Is this application of your clinical problem to the EOP-SLO easy or difficult to think
about competency? Explain
This scholarly project doesn’t directly give recommendations for primary, secondary, or tertiary
prevention. However, this does explore a new area surrounding COVID-19 patients that has
little data. The descriptive nature of the scholarly project helps set the foundation and direction
for further research that further delineates prevention and treatment measures that can be taken to
prevent complications of COVID-19.
C. Looking at the comparison table - how similar or different are the EOP SLOs to its DNP
Essential (as seen on the table)?
This EOP-SLO is only identified in two out of the four entities. The two descriptions of
health promotion are very similar and accurately reflect the meaning of whole-person care.
Health promotion is a holistic approach to the patient’s health experience.
Patient-Centered Care
A. Your identified clinical problem and how do you think you would be able to show
competency with this Scholarly Project?
The purpose of this project is to bring about more information about those that have AF
occurrences while being hospitalized with COVID-19. The intention is to shed light on this topic
that has very little information so that clinicians can be aware of the incidence, LOS, and other
factors related to this population in hopes that it will improve patient outcomes. This topic is
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completely centered around the patient as it is intended to improve those with AF within the
COVID-19 population.
B. Is this application of your clinical problem to the EOP-SLO easy or difficult to think
about competency? Explain
Applying the clinical problem of AF in COVID-19 patients is easy to apply to patientcentered care. The essence of the project is to show who this clinical problem affects patients
with the intention of further research to improve patient care.
C. Looking at the comparison table - how similar or different are the EOP SLOs to its DNP
Essential (as seen on the table)?
Patient centered-care is appreciated as an integral part of all four of the entities that govern
the DNP essentials. Patient centered-care has proven to increase buy-in and compliance of with
the treatment plan, which can only improve patient outcomes. Patient-centered care definition is
similar across all four entities and infers more weight than other essentials due to its presence in
all four lists.
Quality & Safety:
A. Your identified clinical problem and how do you think you would be able to show
competency with this Scholarly Project?
This project is a retrospective descriptive project & has little to no risk. The intent is to learn
about the incidence, LOS, and other related factors in patients with AF occurrences that are
hospitalized for COVID-19.
B. Is this application of your clinical problem to the EOP-SLO easy or difficult to think
about competency? Explain
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This is probably the safest form of research that can be done as there is no interaction or
little to no risk to patients. We can learn a lot from patients’ charts so that we can improve upon
the quality and safety of those with AF while COVID-19 positive.
C. Looking at the comparison table - how similar or different are the EOP SLOs to its DNP
Essential (as seen on the table)?
There is a wide range of definitions across all the DNP essentials related to quality and
safety, however, they all mention something about not harming the patient. While others strive
for organizational quality & leadership quality.
Informatics & Innovation:
A. Your identified clinical problem and how do you think you would be able to show
competency with this Scholarly Project?
This scholarly project is intended to add to the limited data on this topic of AF in COVID-19
patients, which is innovative for this project. The use of the EHR system, EPIC, to collect data is
yet another way that informatics can be used to investigate and do research.
B. Is this application of your clinical problem to the EOP-SLO easy or difficult to think
about competency? Explain
Navigating the hospital system to get access to HER was a lot harder and challenging than I
expected. While the process was fairly simple, it was the first time a DNP student had
navigated it on EPIC and during a pandemic no less, which made it rather a challenge.
C. Looking at the comparison table - how similar or different are the EOP SLOs to its DNP
Essential (as seen on the table)?
Two out of the three entities described innovation and informatics as essentials for the DNPprepared nurse. I believe these two essentials are integral in the future of nursing. Technology
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permeates every aspect of patient care. We need innovative thinking when we approach patient
care challenges and when looking for solutions.
Teamwork & Collaboration:
A. Your identified clinical problem and how do you think you would be able to show
competency with this Scholarly Project?
Collaboration with professors, clinical advisors, and project mentors was essential to the
success of the project. Knowing who to ask questions to when formulating a patient list and
navigating the EHR helps improve the speed and accuracy of the data collected.
B. Is this application of your clinical problem to the EOP-SLO easy or difficult to think
about competency? Explain
Dealing with people can be difficult unless you get their buy-in and they have aninterest in
the project. Carefully selecting members to be involved means creating relationships and
networking with other professionals in the field of interest.
C. Looking at the comparison table - how similar or different are the EOP SLOs to its DNP
Essential (as seen on the table)?
This essential is fairly similar across the three entities, however, there is one that points out
timeliness as a important part of teamwork and collaboration. I also believe that this is true and
an important for a functioning team. It also shows respect to other team members when you are
timely in your work.
Professionalism:
A. Your identified clinical problem and how do you think you would be able to show
competency with this Scholarly Project?
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Yes. I don’t think that professionalism would be hard to accomplish in this type of project
although when working with people there can be a variety of definition of they think
professionalism means. Showing professionalism, as defined by SAU SON standards, would be
important to show when interacting with anyone during the scholarly project. Professionalism
can make an everlasting impression on people that could play an important role in your future
career.
B. Is this application of your clinical problem to the EOP-SLO easy or difficult to think
about competency? Explain
For me, this seems easy, when referring to myself. However, when there is a team involved
you must think that someone may not be professional when interacting with project participants.
This makes me think that I would have to select people (helpers, mentors) who were already
professional to participate in this project to ensure professionalism throughout the project.
C. Looking at the comparison table - how similar or different are the EOP SLOs to its DNP
Essential (as seen on the table)?
SAU SON’s definition of professionalism promotes a nurse that has integrity, morals, and
values. The other entities don’t have professionalism listed not that they probably don’t think it’s
important, however, that it might be a quality that is a given when it comes to essentials seen in
nursing. Although I don’t think it is a given attribute you will find in everyone, therefore you
have to choose your team members wisely when initiating a project.

